US20190316151A1 - Engineered viral vector reduces induction of inflammatory and immune responses - Google Patents
Engineered viral vector reduces induction of inflammatory and immune responses Download PDFInfo
- Publication number
- US20190316151A1 US20190316151A1 US16/167,764 US201816167764A US2019316151A1 US 20190316151 A1 US20190316151 A1 US 20190316151A1 US 201816167764 A US201816167764 A US 201816167764A US 2019316151 A1 US2019316151 A1 US 2019316151A1
- Authority
- US
- United States
- Prior art keywords
- viral genome
- recombinant viral
- seq
- aav
- egfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006698 induction Effects 0.000 title abstract description 24
- 230000028709 inflammatory response Effects 0.000 title description 30
- 230000028993 immune response Effects 0.000 title description 16
- 239000013603 viral vector Substances 0.000 title description 13
- 230000003612 virological effect Effects 0.000 claims abstract description 110
- 230000014509 gene expression Effects 0.000 claims abstract description 44
- 108091035539 telomere Proteins 0.000 claims description 75
- 102000055501 telomere Human genes 0.000 claims description 75
- 150000007523 nucleic acids Chemical group 0.000 claims description 71
- 241000700605 Viruses Species 0.000 claims description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 61
- 239000013598 vector Substances 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 210000002845 virion Anatomy 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 3
- 241000702617 Human parvovirus B19 Species 0.000 claims description 3
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 3
- 241000701460 JC polyomavirus Species 0.000 claims description 3
- 241000700627 Monkeypox virus Species 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 3
- 241000700647 Variola virus Species 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 abstract description 63
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 abstract description 63
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 30
- 230000004913 activation Effects 0.000 abstract description 19
- 108700019146 Transgenes Proteins 0.000 abstract description 17
- 102000003945 NF-kappa B Human genes 0.000 abstract description 11
- 108010057466 NF-kappa B Proteins 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 238000010361 transduction Methods 0.000 abstract description 4
- 230000026683 transduction Effects 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 230000005860 defense response to virus Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 64
- 210000003411 telomere Anatomy 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 54
- 206010061218 Inflammation Diseases 0.000 description 38
- 230000004054 inflammatory process Effects 0.000 description 37
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 34
- 239000013607 AAV vector Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 28
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 23
- 102000003390 tumor necrosis factor Human genes 0.000 description 23
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 16
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 13
- 210000001525 retina Anatomy 0.000 description 13
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 12
- 238000001415 gene therapy Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- 101150053137 AIF1 gene Proteins 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000011870 unpaired t-test Methods 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000046699 human CD14 Human genes 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 244000309459 oncolytic virus Species 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 229950006993 alipogene tiparvovec Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 3
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101150087313 Cd8a gene Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000057248 Lipoprotein(a) Human genes 0.000 description 2
- 108010033266 Lipoprotein(a) Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WHHFZOIADLFZRX-UHFFFAOYSA-N n-[5-[[7-(2-hydroxy-3-piperidin-1-ylpropoxy)-6-methoxyquinazolin-4-yl]amino]pyrimidin-2-yl]benzamide Chemical compound N1=CN=C2C=C(OCC(O)CN3CCCCC3)C(OC)=CC2=C1NC(C=N1)=CN=C1NC(=O)C1=CC=CC=C1 WHHFZOIADLFZRX-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000619884 Homo sapiens Lipoprotein lipase Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000045312 human LPL Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000024275 uncoating of virus Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention is related to the area of viral based therapies. In particular, it relates to recombinant viruses.
- GlyberaTM alipogene tiparvovec
- AAV adeno-associated virus
- LPL human lipoprotein lipase
- AAV is a small, non-enveloped virus that packages a single-stranded linear DNA genome that is approximately 5 kb long, and has been adapted for use as a gene transfer vehicle [4].
- the coding regions of AAV are flanked by inverted terminal repeats (ITRs), which act as the origins for DNA replication and serve as the primary packaging signal [7, 8]. Both positive and negative strands are packaged into virions equally well and capable of infection [9-11].
- ITRs inverted terminal repeats
- Both positive and negative strands are packaged into virions equally well and capable of infection [9-11].
- a small deletion in one of the two ITRs allows packaging of self-complementary vectors, in which the genome self-anneals after viral uncoating. This results in more efficient transduction of cells but reduces the coding capacity by half [12, 13].
- AAV is not associated with any human disease, >70% of humans are seropositive for one or most serotypes [14, 15].
- Typical routes of administration for AAV vectors include intravenous, intramuscular, subretinal and intracranal injections.
- AAV gene therapy is most often used to deliver a wild-type gene to treat monogenic diseases, and AAV vectors have been used to transduce cells in the liver, skeletal and cardiac muscle, retina and central nervous system [16-26].
- AAV CRISPR-Cas9 gene editing or to deliver broadly neutralizing antibodies against infectious diseases such as human immunodeficiency virus (HIV) and influenza A virus [27-32].
- immunosuppressive and anti-inflammatory drugs compromise the patient's immune system during treatment, and all patients still developed neutralizing antibodies against AAV capsid, precluding future re-administration.
- many AAV gene therapy clinical trials do not utilize immunosuppression prophylactically and only administer corticosteroids upon signs of inflammation or tissue damage, which has been associated with variable therapeutic efficacy [22, 23].
- AAV vectors have also been developed as vaccine vehicles against infectious diseases and cancer [39-41].
- Inflammation has been implicated as a critical determinant of successful AAV-mediated transgene expression.
- a study found that following AAV administration in mice, artificially inducing systemic inflammation such as the upregulation of tumor necrosis factor (TNF), led to a decline in transgene expression in the liver [42]. This indicates that immunological tolerance to AAV-encoded transgene can be broken given sufficient inflammatory responses.
- TNF tumor necrosis factor
- Another study characterized inflammation in the murine liver following AAV infection and found transient increases in liver enzymes in the serum, and also liver pathology consistent with portal and lobular inflammation [43].
- TLR9 Toll-like receptor 9
- PRR pattern recognition receptor
- NF-kB in turn drives the transcriptional upregulation of multiple proinflammatory cytokines such as TNF leading to inflammation and immune cell recruitment, while secreted IFNs induce the expression of numerous interferon-stimulated genes (ISGs) and establish an antiviral state.
- ISGs interferon-stimulated genes
- TLR9 plays a critical role in stimulating an early inflammatory and innate immune response during AAV infection, which also contributes to priming adaptive immunity.
- TLR2 and TLR4 have been implicated in triggering responses to AAV structural proteins [47, 48].
- TLR9 In the TLR9 field, a commonly used tool to block TLR9 activation in cell culture is short, single-stranded DNA oligonucleotides that bind TLR9 but do not activate it [49, 50]. Several such sequences are known—some synthetic and others derived from organisms—and they often bear no sequence homology [51-59]. Structural studies have revealed how an inhibitory oligonucleotide binds TLR9 tightly but does not trigger TLR9 dimerization, which is required for TLR9 activation and downstream signaling [60].
- TLR9-inhibitory oligonucleotides In addition to binding TLR9 directly to antagonize its activation, other mechanisms to block TLR9 activation or TLR9-mediated inflammation have been postulated or shown for other TLR9-inhibitory oligonucleotides [reviewed in 49]. These include competing for receptor-mediated endocytosis or phagocytosis, inhibition of TLR9 trafficking or TLR9 processing into a functionally active product, inhibition of endosomal acidification or activity of key proteases in endosomes, or blocking signaling proteins downstream of TLR9.
- inhibitory oligonucleotides When these inhibitory oligonucleotides are supplied in trans with TLR9 ligands (such as a DNA virus, or a CpG-containing oligonucleotide) in cell culture media, they are endocytosed and can bind to TLR9, preventing its activation by stimulatory ligands. Supplementation of inhibitory oligonucleotides in trans is widely adopted in immunology experiments, but it is unknown in the field if incorporation of these sequences into a viral genome allows it to evade eliciting inflammatory and immune responses.
- TLR9 ligands such as a DNA virus, or a CpG-containing oligonucleotide
- GlyberaTM alipogene tiparvovec treatment still includes twelve weeks of immunosuppression, beginning three days before GlyberaTM alipogene tiparvovec administration.
- These immunosuppressive drugs strongly hamper T cell activation and therefore compromise the patient's immune system during treatment. It would be advantageous to engineer viral vectors that evade and elicit diminished or no inflammatory response upon administration. Furthermore, it would be beneficial if the immune suppression was not systemic, and if it was transient. Preventing inflammatory and immune responses could also improve transgene expression and may allow the re-administration of the viral vector for future purposes.
- a nucleic acid molecule comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- a recombinant virus for delivery of a desired function to a mammalian cell.
- the recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- Another embodiment is an aspect of treating a mammal.
- the method comprises administering a recombinant virus to a mammal in need thereof.
- the recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- Still another aspect is a method of making a viral genome of a recombinant virus.
- An inhibitory nucleic acid sequence is inserted into a viral genome.
- the inhibitory nucleic acid sequence binds to TLR9 but does not trigger TLR9 activation.
- a nucleic acid molecule comprises an inverted terminal repeat (ITR) and a nucleic acid sequence which inhibits TLR9-mediated inflammation.
- ITR inverted terminal repeat
- the molecule comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.
- Yet another aspect of the invention is a recombinant virus for delivery of a desired function to a mammalian cell.
- the recombinant virus comprises a viral genome comprising an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.
- Still another aspect of the invention is a method of making a viral genome of a recombinant virus.
- a nucleic acid sequence is inserted into a viral genome.
- the nucleic acid sequence inhibits TLR9-mediated inflammation.
- a nucleic acid vector comprising at least one nucleic acid sequence.
- the nucleic acid sequence is capable of inhibiting TLR9-mediated inflammation.
- Another aspect of the invention is a method of reducing immunogenicity of a modified virus having a genome.
- the method comprises inserting a nucleic acid sequence into the genome.
- the nucleic acid sequence inhibits TLR9-mediated inflammation.
- the modified virus causes a reduced inflammatory response in a host as compared to a virus that does not contain the inhibitory sequence.
- Still another aspect of the invention is a method of increasing expression in a host cell of a virally introduced transgene.
- the method comprises introducing into a host a modified virus having a genome.
- the genome comprises a nucleic acid sequence.
- the nucleic acid sequence inhibits TLR9-mediated inflammation.
- the modified virus results in higher transgene expression in a host cell as compared to a virus that does not contain the inhibitory sequence.
- compositions comprising a viral capsid encapsidating a nucleic acid sequence that inhibits TLR9-mediated inflammation.
- the viral genome may be adeno-associated virus (AAV) genome.
- AAV adeno-associated virus
- the viral genome may be selected from the group consisting of adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, and human parvovirus B19.
- the viral genome may be single stranded.
- the viral genome may be packaged in a virion.
- the viral genome may comprise a gene which may be expressible in a human cell.
- the viral genome may be a cytotoxic virus for lysing target tumor cells.
- the inhibitory nucleic acid sequence may comprise c41 oligonucleotide sequence TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1).
- the inhibitory nucleic acid sequence may comprise a plurality of copies of c41 sequence (SEQ ID NO: 1).
- the inhibitory nucleic acid sequence may comprise two copies of c41 sequence (SEQ ID NO: 1) separated by a linker sequence.
- the linker sequence is AAAAA (SEQ ID NO: 8).
- the inhibitory nucleic acid sequence may be selected from the group consisting of:
- ODN 2088 (SEQ ID NO: 2) TCC TGG CGG GGA AGT; ODN 4084-F: (SEQ ID NO: 3) CCTGGATGGGAA; ODN INH-1: (SEQ ID NO: 4) CCTGGATGGGAATTCCCATCCAGG; ODN INH-18: (SEQ ID NO: 5) CCT GGA TGG GAA CTT ACC GCT GCA; ODN TTAGGG: (SEQ ID NO: 6) TT AGG GTT AGG GTT AGG GTT AGG GTT AGG G; and G-ODN: (SEQ ID NO: 7) CTC CTA TTG GGG GTT TCC TAT.
- the inhibitory nucleic acid sequence may be a bacterial sequence.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human gene.
- the inhibitory nucleic acid sequence may be inserted downstream of or in a 3′ untranslated region of the viral genome.
- the viral genome may be covalently linked to the inhibitory nucleic acid sequence by a phosphodiester bond.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a detectable marker.
- the detectable marker may be inducible.
- the inhibitory nucleic acid sequence may comprise a human telomere sequence shown in SEQ ID NO: 9.
- the viral genome may be self-complementary.
- the viral genome may be covalently linked to a plurality of inhibitory nucleic acid sequences.
- the plurality of inhibitory nucleic acid sequences may comprise an inhibitory sequence and its reverse complement.
- the inhibitory nucleic acid sequence may comprise three copies of c41 sequence (SEQ ID NO: 1), each copy separated by a linker sequence.
- the inhibitory nucleic acid sequence may be selected from the group consisting of:
- ODN 2114 (SEQ ID NO: 16) TCCTGGAGGGGAAGT; ODN 4024: (SEQ ID NO: 17) TCCTGGATGGGAAGT; ODN INH-4: (SEQ ID NO: 18) TTCCCATCCAGGCCTGGATGGGAA; ODN INH-13: (SEQ ID NO: 19) CTTACCGCTGCACCTGGATGGGAA; ODN Poly-G: (SEQ ID NO: 20) GGGGGGGGGGGGGGGGGGGGGG; ODN GpG: (SEQ ID NO: 21) TGACTGTGAAGGTTAGAGATGA; ODN IRS-869: (SEQ ID NO: 22) TCCTGGAGGGGTTGT; ODN IRS-954: (SEQ ID NO: 23) TGCTCCTGGAGGGGTTGT; and ODN 21158: (SEQ ID NO: 24) CCTGGCGGGG.
- the inhibitory nucleic acid sequence may be ODN TTAGGG (SEQ ID NO: 6).
- the inhibitory sequence may be covalently linked to a linker.
- the inhibitory sequence may be upstream of the linker.
- the inhibitory nucleic acid sequence may comprise a plurality of copies of ODN TTAGGG (SEQ ID NO: 6).
- the plurality of copies of ODN TTAGGG may each be separated by a linker.
- the inhibitory nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of ODN TTAGGG (SEQ ID NO: 6), each copy separated by a linker.
- the inhibitory nucleic acid sequence may be a human sequence.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human nucleic acid sequence.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human gene.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human nucleic acid sequence.
- the inhibitory nucleic acid sequence may be inserted in the 5′ untranslated region of the viral genome.
- the inhibitory nucleic acid sequence may be inserted upstream of a promoter of the viral genome.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise an inducible promoter.
- the inhibitory nucleic acid sequence may comprise two repeated monomers of SEQ ID NO: 1.
- the inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 1.
- the inhibitory nucleic acid sequence may comprise SEQ ID NO: 6 or SEQ ID NO: 9.
- the inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.
- the inhibitory nucleic acid sequence may comprise five repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.
- the step of administering may be repeated.
- the viral genome may be packaged in virions.
- the step of inserting may utilize a DNA ligase.
- the viral genome may be single stranded when in virions.
- the viral genome of the recombinant virus may comprise a gene for delivery to and expression in a human cell.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a linker separating each of the nucleic acid sequences.
- the viral genome, recombinant virus, vector, or nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of the nucleic acid sequence.
- the inhibitory nucleic acid may be covalently linked to a gene.
- the inhibitory nucleic acid sequence may be 95% identical to c41 oligonucleotide sequence TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1).
- the inhibitory nucleic acid sequence may be 95% identical to SEQ ID NO: 9.
- the inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:
- ODN 2088 (SEQ ID NO: 2) TCC TGG CGG GGA AGT; ODN 4084-F: (SEQ ID NO: 3) CCTGGATGGGAA; ODN INH-1: (SEQ ID NO: 4) CCTGGATGGGAATTCCCATCCAGG; ODN INH-18: (SEQ ID NO: 5) CCT GGA TGG GAA CTT ACC GCT GCA; ODN TTAGGG: (SEQ ID NO: 6) TT AGG GTT AGG GTT AGG GTT AGG GTT AGG G; and G-ODN: (SEQ ID NO: 7) CTC CTA TTG GGG GTT TCC TAT.
- the inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:
- ODN 2114 (SEQ ID NO: 16) TCCTGGAGGGGAAGT; ODN 4024: (SEQ ID NO: 17) TCCTGGATGGGAAGT; ODN INH-4: (SEQ ID NO: 18) TTCCCATCCAGGCCTGGATGGGAA; ODN INH-13: (SEQ ID NO: 19) CTTACCGCTGCACCTGGATGGGAA; ODN Poly-G: (SEQ ID NO: 20) GGGGGGGGGGGGGGGGGGGGGG; ODN GpG: (SEQ ID NO: 21) TGACTGTGAAGGTTAGAGATGA; ODN IRS-869: (SEQ ID NO: 22) TCCTGGAGGGGTTGT; ODN IRS-954: (SEQ ID NO: 23) TGCTCCTGGAGGGGTTGT; and ODN 21158: (SEQ ID NO: 24) CCTGGCGGGG.
- the inhibitory nucleic acid sequence may comprise a plurality of copies of SEQ ID NO: 6 and/or SEQ ID NO: 9
- the inhibitory nucleic acid sequence may comprise two copies of SEQ ID NO: 6 and/or SEQ ID NO: 9 separated by a linker sequence.
- FIG. 1 Schematic drawing of viral gene therapy and inflammatory and immune responses.
- FIG. 2 Schematic drawing showing TLR9 sensing AAV DNA during viral entry and inflammatory and immune responses. From Rogers et al., 2011, Frontiers in Microbiology, “Innate Immune Responses to AAV Vectors,” vol. 2, article 194.
- FIGS. 3A-3B show nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide.
- FIG. 3B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LPA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted in FIG. 3B is shown in SEQ ID NO: 8.
- FIG. 4 shows NF-kB activity in HEK293 TLR9 cells mock-infected or infected with AAV virus (DJ capsid, self-complementary AAV genome, encoding eGFP). **, p ⁇ 0.005; n.s., not significant. This experiment used a crude viral preparation.
- FIG. 5 Flow cytometry histograms showing GFP expression in HEK293 TLR9 cells mock-infected or infected with AAV virus with or without c41. This experiment used a crude viral preparation.
- FIGS. 6A-6B show nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG) 4 (SEQ ID NO: 6) motif from mammalian telomeres.
- FIG. 6B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown in FIG. 6B are SEQ ID NO: 8.
- FIGS. 7A-7B show the percentage of transduced cells (GFP+) 2 days after infection of a B cell line with similar amounts of indicated AAV viruses, analyzed by flow cytometry.
- FIG. 7B shows TNF production in the supernatant of primary human CD14+ monocytes 18 hours after infection, as assayed by ELISA.
- FIG. 8A-8B Engineering a self-complementary AAV vector.
- FIG. 8A DNA sequences of “c41” and “telomere”.
- FIG. 8B Genome organization of an AAV vector (scAAV-eGFP) and modified vectors.
- LpA polyA signal.
- FIG. 9A-9C Inflammatory response to various AAV vectors in human immune cells in vitro.
- FIG. 9A Primary human macrophages were infected with AAV2 viruses (MOI: 10 5 vg/cell) and supernatants were collected 18 h later and analyzed by ELISA for TNF levels. Five uM ODN 2006, a CpG-containing oligonucleotide, served as a positive control.
- FIG. 10A-10E Further characterization of AAV vectors.
- FIG. 10A DNA sequence of “control”.
- FIG. 10B Genome organization of modified vectors.
- FIG. 10C Primary human macrophages were infected with AAV2 viruses similar to ( FIG. 9A ) and analyzed by ELISA for TNF levels.
- FIG. 11A-11B Primary human macrophages using a different lot of both AAV2 viruses were infected similar to ( FIG. 9A ) and analyzed for TNF levels.
- FIG. 12A-12C Inflammatory response to intravenous administration of various AAV vectors in adult mice in vivo.
- FIG. 13 Genome organization of a single-stranded AAV vector (ssAAV-eGFP) and ssAAV-eGFP-5 ⁇ telomere.
- FIG. 14A-14C Inflammatory and immune response following subretinal administration of various AAV vectors in neonatal mice in vivo.
- Neonatal CD1 mice P1 received indicated AAV8 viruses (1.8 ⁇ 10 8 vg per mouse eye) by subretinal injections.
- the animals were euthanized and the eyecup was dissected out.
- the retina and the rest of the eyecup were analyzed for indicated gene expression by qRT-PCR. Saline injection was set to 1 fold expression for each gene.
- FIG. 15A-15C Analysis of immune cell markers in the retina following subretinal administration of various AAV vectors in neonatal mice in vivo.
- FIG. 15A , FIG. 15B and FIG. 15C Similar to ( FIG. 14A-14C ), the retina was analyzed for indicated gene expression by qRT-PCR.
- Aif1 (Iba1) is known to be expressed in microglia, while Cd4 and Cd8a are markers of helper and cytolytic T cells respectively.
- FIG. 16 GFP expression in the eye.
- Neonatal CD1 mice P1 received indicated AAV8 viruses (1.8 ⁇ 10 8 vg per mouse eye) by subretinal injections.
- FIGS. 17A-17B show nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide.
- FIG. 17B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LPA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted in FIG. 17B is shown in SEQ ID NO: 8.
- FIGS. 18A-18B show nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG) 4 (SEQ ID NO: 6) motif from mammalian telomeres.
- FIG. 18B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown in FIG. 18B are SEQ ID NO: 8.
- the inventors have developed viral vectors and virions that harbor their own protection against host immune and inflammatory systems. These vectors and virions carry short nucleic acid sequences which inhibit the activation of toll-like receptor 9 (TLR9), a host protein which activates inflammatory and immune responses in mammalian cells.
- TLR9 toll-like receptor 9
- a short nucleotide sequence for inhibition of TLR9 may be of any origin. It can be bacterial, human, synthetic, or from other sources.
- One particular sequence is the 20 nucleotide long “c41” [TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1)] from Pseudomonas aeruginosa .
- Another particular sequence is from human telomeres and comprises (TTAGGG) 4 (SEQ ID NO:6).
- Other inhibitory sequences are shown in SEQ ID NO: 2-5, 7, 9, and 16-24. Inhibitory sequences may also be used which share at least 80% homology/identity with these sequences.
- Inhibitory sequences may also be used which share at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and/or at least 99% homology/identity with these sequences.
- Multiple copies of the inhibitory sequence can be used, either in tandem arrays or separated in the viral vector by spacer or linker sequences or other portions of the viral genome. In some embodiments one, two, three, four, five, six, seven, eight, nine, ten, fifteen, or twenty copies are used. In some embodiments one or more copies of the inhibitory sequence are on the plus strand and some on the minus strand of the virus genome.
- the inhibitory oligonucleotide sequences are introduced into host cells as part of the viral genome or virion, rather than as a separate agent. This renders the effect of the oligonucleotide sequences local rather than systemic. Moreover, the immune evasion is transient as it occurs during AAV or other virus entry, unlike immune suppression with drugs which can last for weeks. Additionally, it ensures that the beneficial antagonist activity is where it needs to be—with the virus or viral genome. If the virus or viral genome is not replicated in the host cell, then the effect of the oligonucleotide will be transient. If the virus or viral genome is replicated, the effect will be coextensive with the replication.
- An inhibitory nucleic acid sequence may be inserted into a viral genome using any means of recombinant DNA engineering. This may involve in vitro or in vivo recombination. In vitro recombination may be accomplished using a DNA ligase or other nucleic acid joining enzyme, for example. In vivo recombination may be accomplished by co-transforming a host cell with separate donor molecules that share homology by which they will recombine using host cell machinery. Alternatively, a single donor molecule may recombine in vivo with a host cell sequence. Combinations of these approaches may also be used. Typically the insertion will involve a standard linkage of one deoxyribonucleotide to another (a phosphodiester bond). However, there may be circumstances in which non-standard linkages will be used between the inhibitory nucleic acid sequence and the rest of the viral genome. Optionally, the inhibitory nucleic acid sequence is located in an untranslated region of the viral genome.
- the genome may optionally contain a therapeutic gene and/or a marker gene.
- this gene will be a non-viral gene, or a gene that is not naturally present in the viral genome.
- the gene may be expressible in a mammalian host cell or animal. Expression may be under the control of a viral promoter or a promoter that is introduced with the gene. Expression may be inducible, repressible, condition-responsive, or constitutive, as examples.
- a therapeutic gene is one which encodes an RNA or protein product beneficial to the host. The benefit may be, for example, to improve health, protect against infection, or remedy a deficiency.
- the marker may enable one to track the location, the level of replication, the level of propagation, the level of transcription, or the level of translation of the virus or its products or components.
- Suitable markers include those which are readily detectable, such as fluorescent proteins, chromogenic proteins, etc.
- a second agent may be used or added for detection of the marker protein or for development of a detectable substance. Introduced genes may be human or non-human, heterologous (from another species) or homologous (from same species) or endogenous (from the same subject).
- Any DNA viral genome can be used, whether single stranded or double stranded.
- suitable viruses include without limitation, wild-type or variants of adeno-associated virus (AAV), adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, human parvovirus B19, and enterovirus.
- AAV adeno-associated virus
- adenovirus herpes simplex virus
- varicella varicella
- variola virus hepatitis B
- JC polyomavirus JC polyomavirus
- BK polyomavirus monkeypox virus
- Herpes Zoster Epstein-Barr virus
- human herpes virus 7 Kaposi's sar
- Viral vectors in which viral genomes have been modified may also be used.
- a genome that is modified to encode fewer viral proteins may be used.
- a viral genome that is modified to encode no viral proteins may be used.
- Viral genomes may include, by way of non-limiting example, inverted terminal repeats and/or other non-coding genetic elements that facilitate packaging of engineered viral genomes into the capsid.
- Viral genomes may be delivered to a mammalian host cell as naked DNA, in a liposome, complexed to a polymer, in a condensed or compacted state, in a gold particle, in a virion, or any other means that is suitable for the application.
- a complete viral genome will be administered, but in some situations, it may be desirable to use a partial genome.
- the partial genome may be complemented by helper functions provided by the host cell or another genomic or viral entity. Partial genomes may be used, for example, if the therapeutic payload is large and some essential viral functions must be omitted to package.
- Recombinant viruses may be administered to a mammal or mammalian cells according to any route which is effective for the purpose.
- the administration may be systemic, e.g., via the blood. It may be delivered orally, subcutaneously, topically, bucally, anally, intramuscularly, intravenously, intratumorally, intracranially, intrathecally, subretinally, etc. Any suitable carrier or vehicle may also be used for administration. It may be desirable to pre-treat the cells or mammal to render them more permeable to or receptive to the recombinant virus. A mammal “in need of” a recombinant virus may be one for whom the virus will be beneficial.
- the inhibitory nucleic acid sequences we used, as well as others known in the art, may be incorporated into other viruses that, like AAV, have potential utility for humans and other mammals but elicit inflammatory/immune responses that may be undesirable.
- oncolytic viruses that preferentially infect and lyse cancer cells are used to kill or shrink tumors. These viruses are replicative (unlike AAV vectors used for gene therapy) so they can release new virions to shrink the remaining tumor. Examples include wild-type or variants of herpes simplex virus, adenovirus, and enterovirus.
- Some reports have shown that immunosuppression by chemotherapy can enhance oncolytic virus therapy, as the immune system normally attempts to inactivate the oncolytic virus, which would prevent it from infecting cancer cells. Therefore, it is possible that incorporating inhibitory oligonucleotides in the genomes of oncolytic viruses like herpes simplex virus may allow it to evade immune clearance and persist longer for oncolysis.
- AAV vector that has the ability to specifically evade TLR9 activation in immune cells
- c41 separated by a 5-nucleotide-long spacer (AAAAA; SEQ ID NO: 8) into the 3′ untranslated region of AAV vector encoding enhanced green fluorescent protein (eGFP)
- eGFP enhanced green fluorescent protein
- HEK293 cells stably expressing TLR9 HEK293 TLR9 cells
- NF-kB alkaline phosphatase
- alkaline phosphatase is secreted into the media and acts on a provided substrate, leading to a change in color of the media that can be measured on a plate reader.
- AAV-eGFP infection induced a small but statistically significant increase in NF-kB activity ( FIG. 4 ).
- AAV-eGFP-c41 infection was not significantly different compared to mock-infected cells, indicating that the virus was able to evade eliciting an inflammatory response.
- telomere a sequence derived from mammalian telomeres that contains the suppressive (TTAGGG) 4 motif (SEQ ID NO: 6), which has been shown to block TLR9 signaling ( FIG. 6A and FIG. 6B ).
- AAV-eGFP-telomere virus yielded similar viral titers as AAV-eGFP and AAV-eGFP-c41 when titered on HeLa cells, demonstrating that incorporation of “telomere” does not hinder viral packaging and infectivity.
- both AAV-eGFP-c41 and AAV-eGFP-telomere viruses transduced more cells than AAV-eGFP ( FIG. 7A ). This finding suggests too that incorporation of inhibitory sequences in the genome of AAV increases transgene expression.
- TNF is a prototypical pro-inflammatory cytokine induced by NF-kB activation.
- AAV-eGFP infection increased TNF production compared to mock-infection, while AAV-eGFP-c41 and AAV-eGFP-telomere infections showed no or little increase in TNF production ( FIGS. 7A-7B ), showing that the two viruses were able to evade eliciting inflammatory responses.
- inhibitory oligonucleotides typically 10-30 nucleotides in length
- eGFP enhanced green fluorescent protein
- telomere derived from bacteria and mammalian telomeres respectively [52, 57, 58, 61]
- sc AAV vectors As they have been shown to be more efficient at triggering TLR9 activation and inducing more inflammation in the mouse liver than single-stranded (ss) AAV vectors.
- ss single-stranded
- c41 and telomere are predicted to have strong secondary structure, we used an AAAAA linker between copies of the inhibitory oligonucleotide.
- telomere sequences were placed after the polyA sequence and upstream of the right inverted terminal repeat (ITR) so they would be present in the DNA genome during viral entry, but would be absent from subsequent mRNA transcripts upon successful transduction (“scAAV-eGFP-3 ⁇ c41” and “scAAV-eGFP-3 ⁇ telomere”).
- ITR right inverted terminal repeat
- AAV2 serotype and infected primary human monocyte-derived macrophages at a multiplicity of infection (MOI) of 10 5 viral genomes (vg) per cell.
- MOI multiplicity of infection
- scAAV-eGFP infection of macrophages elicited robust induction of TNF in the supernatant, a prototypical inflammatory cytokine with well-described roles in stimulating fever, apoptosis and inflammation, and is produced upon TLR9 signaling and NF-kB activation ( FIG. 9A ).
- scAAV-eGFP-3 ⁇ 41 and scAAV-eGFP-3 ⁇ telomere markedly decreased TNF induction by >95%, indicating that incorporation of “c41” or “telomere” in these viruses could evade eliciting inflammatory responses compared to the wild-type (WT) vector.
- WT wild-type
- scAAV-3 ⁇ telomere-eGFP was also able to prevent TNF induction by >95%, demonstrating that the inserted inhibitory oligonucleotides can be placed in other parts of the viral genome and retain the ability to block inflammation.
- telomere As further characterization, we inserted 3 copies of “control,” a random sequence that does not block TLR9, or 1 copy of “telomere”, into a plasmid harboring the vector genome ( FIG. 10A , FIG. 10B ). We picked the sequence “control” as it has been used as a negative control oligonucleotide in TLR9 experiments. We found that scAAV-eGFP-lx telomere was able to reduce TNF induction compared to scAAV-eGFP in human macrophages, but not as efficiently as scAAV-eGFP-3 ⁇ telomere ( FIG. 10C ). This indicates that 1 copy of telomere can reduce inflammation.
- AAV vectors are considered biologics and may exhibit lot-to-lot variability
- FIGS. 9A-9C , FIGS. 10A-10E and FIGS. 11A-11B we conclude that our engineered vectors containing 3 copies of “c41” or “telomere” reduce TNF induction by approximately 75-98% compared to the WT vector.
- scAAV-eGFP-3 ⁇ telomere reduced ⁇ 85% of TNF induction compared to scAAV-eGFP.
- Intravenous delivery of AAV is often used to transduce hepatocytes for gene therapy.
- Kupffer cells resident hepatic antigen-presenting cells
- inflammatory and innate immune responses 1-9 h later [36].
- These responses include induction of proinflammatory cytokines such as TNF and IL6 and type I interferons such as IFN- ⁇ .
- TLR9 ⁇ / ⁇ mice do not exhibit these inflammatory and innate immune responses in the liver, demonstrating a central role for TLR9 in vivo as an innate immune sensor.
- telomere a telomere derived from human sequences and might be preferable for clinical use.
- Example 8 Engineing a Single-Stranded AAV Vector and Determining Inflammatory Responses in Eye Tissues of Mice In Vivo
- ssAAV-eGFP single-stranded AAV vector, ssAAV-eGFP, by inserting 5 copies of “telomere” with AAAAA linkers, followed by another 5 copies but in anti-sense orientation, into the plasmid, giving ssAAV-eGFP-5 ⁇ telomere ( FIG. 13 ). Since both positive and negative strands of the viral genome are equally likely to be packaged into a viral particle, this ensures that each packaged viral genome would have 5 copies of “telomere” in the correct orientation.
- Two AAV8 viruses were produced and purified. Again, we did not observe differences in titers between the two vectors, suggesting similar packaging efficiency (data not shown). ssAAV-eGFP was selected as it has been previously used for subretinal injections in mice and efficiently transduces photoreceptors in the eye [62].
- ssAAV-eGFP or ss-AAV-eGFP-5 ⁇ telomere were delivered via subretinal injection into neonates eyes and measured the expression of inflammatory and immune genes.
- the three mice that received saline injections were uniformly low for Tnf expression in the retina and were set to 1 fold expression ( FIG. 14A ).
- two mice that received ssAAV-eGFP two exhibited mild upregulation of Tnf (1.9 fold and 8.3 fold), while three animals demonstrated large induction of Tnf (62.2 fold, 534 fold, and 1003 fold), with a mean of 321 fold for the five animals.
- the engineered vector is able to reduce inflammatory and immune responses in the retina and also augment transgene expression.
- mice Male, 7-9 weeks old were purchased from the Jackson Laboratory and CD1 mice were purchased from Charles River Laboratories.
- scAAV-eGFP Single-stranded AAV vectors were used in this study.
- Self-complementary vectors lack the terminal resolution sequence in one ITR. All vector genomes were flanked by AAV2 ITRs.
- scAAV-eGFP was purchased from Cell Biolabs (VPK-430) and has been previously described [73].
- scAAV-eGFP expressed enhanced green fluorescent protein (eGFP) from the cytomegalovirus (CMV) promoter, and included an SV40 intron and SV40 polyA sequence.
- ssAAV-eGFP has been previously described [62] and was originally obtained from the Harvard DF/HCC DNA Resource Core (clone ID: EvN000061595).
- ssAAV-eGFP contained a CMV enhancer/promoter, human ⁇ -globin intron, eGFP, and ⁇ -globin polyA sequence.
- the sequences of “c41” (5′-TGGCGCGCACCCACGGCCTG-3′; SEQ ID NO: 1) derived from Pseudomonas aeruginosa and “telomere” (5′-TTTAGGGTTAGGGTTAGGGTTAGGG-3′; SEQ ID NO: 9; initial T nucleotide is optional for function) derived from mammalian telomeres have been described [52, 57, 58, 61].
- telomere A widely used “telomere” oligonucleotide (manufactured by Invivogen, catalog code “tlrl-ttag”) harbored an additional T (in bold) compared to published studies and thus was included in the sequence. During the course of this study, Invivogen removed the additional T in their manufactured “telomere” oligonucleotide (catalog code “tlrl-ttag151”). In addition, “control” (5′-GCTAGATGTTAGCGT-3′; SEQ ID NO: 34) was used as a negative control sequence that does not inhibit TLR9 activation (Invivogen, catalog code “tlrl-2088c”).
- sequences were inserted into the unique SpeI site found immediately 5′ of the right ITR.
- a unique ClaI site was created immediately 5′ of the inserted sequences, thus allowing ClaI/SpeI sub-cloning of sequences.
- 3 copies of “c41,” “telomere,” or “control” were inserted, separated by AAAAA linkers, giving scAAV-eGFP-3 ⁇ c41, scAAV-eGFP-3 ⁇ telomere and scAAV-eGFP-3 ⁇ control, respectively.
- telomere Alternatively, one copy of “telomere” was inserted, with an AAAAA linker (SEQ ID NO: 8), giving scAAV-eGFP-lx telomere.
- AAAAA linker SEQ ID NO: 8
- telomere 3 ⁇ telomere between the left ITR and CMV promoter using the unique AvrII site, giving scAAV-3 ⁇ telomere-eGFP.
- telomere(sense)-5 ⁇ telomere(anti-sense)-NheI was inserted immediately 5′ of the XbaI site adjacent to the right ITR.
- AAAAA was used as a linker between copies of “telomere”.
- sense and anti-sense sequences of “telomere” were added as single-stranded AAV vectors have an equal chance of packaging positive or negative strands of the viral genome, thus ensuring that all packaged AAV genomes will carry 5 copies of “telomere” in the right orientation.
- Self-complementary vectors were packaged into AAV2 (Vigene Biosciences) by triple transfection of HEK293 cells and purified using iodixanol gradient ultracentrifugation and then concentrated to 500 ul using Amicon Ultra-15 columns in PBS.
- the purified viruses were titered by qPCR using primers derived from ITR and an AAV standard. The final yield of the viruses ranged from 0.5-3 ⁇ 10 13 vg.
- AAV8 Single-stranded vectors were packaged into AAV8 based on previously described protocols [74, 75]. Briefly, AAV vector, rep2-cap8 packaging plasmid and adenoviral helper plasmid were transfected into HEK293T cells with polyethylenimine and supernatant was collected 72 h after transfection. AAV8 viruses were precipitated with 8.5% w/v PEG8000 and 0.4M NaCl and centrifuged at 7000 g. The pellet was resuspended in lysis buffer (150 mM NaCl and 20 mM Tris, pH 8.0) and MgCl2 was added to a final concentration of 1 mM.
- lysis buffer 150 mM NaCl and 20 mM Tris, pH 8.0
- the resuspended viruses were incubated with 25 U/ml Benzonase (Sigma) at 37° C. for 15 min and run on an iodixanol gradient. Recovered AAV vectors were washed 3 times with PBS using Amicon 100K columns (EMD Millipore) and concentrated to 100-500 ul of PBS. Protein gels were run to determine virus titers, using serial dilutions of previous AAV standards for comparison.
- PBMCs Human peripheral blood mononuclear cells
- ZenBio Human peripheral blood mononuclear cells
- CD14+ monocytes were positively selected from PBMCs using anti-CD14 magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec) or purchased from Stemcell Technologies.
- monocyte-derived macrophages monocytes were cultured with 50 ng/ml of recombinant human macrophage colony stimulation factor (rhM-CSF, purchased from Peprotech) for 5 to 6 d to allow differentiation into macrophages.
- rhM-CSF recombinant human macrophage colony stimulation factor
- HeLa cells are highly permissive for AAV2 vectors and are commonly used to determine the transducing titer of AAV2 vector preparations [76]. Briefly, HeLa cells were seeded overnight in 12 wells and were approximately 80% confluent at time of infection (3 ⁇ 10 5 cells). Cells were infected with serial ten-fold dilutions of viruses at indicated MOIs and incubated for 48 h before fixing with 1% paraformaldehyde in PBS and followed by flow cytometry analysis for GFP+ cells. PBS mock-infected cells were used to determine GFP+ signal.
- RNAlater solution (OMEGA Bio-Tek).
- RNA-to-cDNA kit Similar amounts of RNA were reverse transcribed into cDNA with a high-capacity RNA-to-cDNA kit (Thermo Scientific) and similar amounts of cDNA were assayed with quantitative PCR (qPCR) using TaqMan Fast Advanced Master Mix (Thermo Scientific) and commercially available pre-designed primers/probes with FAM reporter dye for the indicated target genes (IDT).
- qPCR quantitative PCR
- qMan Fast Advanced Master Mix Thermo Scientific
- IDT FAM reporter dye for the indicated target genes
- Expression level for each gene was calculated by normalizing against the housekeeping genes Actb or Gapdh using the AACT method and expressed as fold levels compared to saline-injected mice. All qPCR reactions were run on a realplex 4 Mastercycle (Eppendorf).
- Eye cups were dissected out by removing the cornea, lens, iris, vitreous body and peripheral muscles. Images of flat-mounted eye cups were taken using a ⁇ 10 objective on a Keyence BZ-x700 microscope. Images used for comparison between groups were taken at the same imaging settings in the same imaging session.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application is continuation of PCT/US2017/036525 filed Jun. 8, 2017, which claims priority to U.S. Provisional Application No. 62/347,302 filed on Jun. 8, 2016, each of which is herein incorporated by reference in its entirety for all purposes.
- This invention was made with government support under Grant No. HG008525 awarded by National Institutes of Health. The government has certain rights in the invention.
- This invention is related to the area of viral based therapies. In particular, it relates to recombinant viruses.
- Gene therapy has immense potential to prevent, treat, and cure multiple human diseases [1]. In 2012, Glybera™ (alipogene tiparvovec) became the first viral gene therapy to be approved for use in the western world [2]. Glybera™ utilizes adeno-associated virus (AAV) as a viral vector to deliver the human lipoprotein lipase (LPL) gene to muscle cells in patients with LPL deficiency [3]. Many AAV clinical trials are currently underway or being planned in the U.S. and the EU [4-6].
- AAV is a small, non-enveloped virus that packages a single-stranded linear DNA genome that is approximately 5 kb long, and has been adapted for use as a gene transfer vehicle [4]. The coding regions of AAV are flanked by inverted terminal repeats (ITRs), which act as the origins for DNA replication and serve as the primary packaging signal [7, 8]. Both positive and negative strands are packaged into virions equally well and capable of infection [9-11]. In addition, a small deletion in one of the two ITRs allows packaging of self-complementary vectors, in which the genome self-anneals after viral uncoating. This results in more efficient transduction of cells but reduces the coding capacity by half [12, 13]. While AAV is not associated with any human disease, >70% of humans are seropositive for one or most serotypes [14, 15]. Typical routes of administration for AAV vectors include intravenous, intramuscular, subretinal and intracranal injections. AAV gene therapy is most often used to deliver a wild-type gene to treat monogenic diseases, and AAV vectors have been used to transduce cells in the liver, skeletal and cardiac muscle, retina and central nervous system [16-26]. In addition, there is now growing interest in using AAV to deliver CRISPR-Cas9 gene editing or to deliver broadly neutralizing antibodies against infectious diseases such as human immunodeficiency virus (HIV) and influenza A virus [27-32].
- Despite several advances in gene therapy, a key concern is the inflammatory response elicited by the viral vector [33, 34]. This is best illustrated by a highly publicized case in 1999 when Jesse Gelsinger died four days after gene therapy with adenovirus in a clinical trial due to excessive inflammation [35]. While AAV has been shown to elicit much weaker inflammation in comparison to adenoviruses [36, 37], Glybera™ therapy still includes twelve weeks of immunosuppression, beginning three days before Glybera™ administration [38]. These immunosuppressive and anti-inflammatory drugs (cyclosporine A, mycophenolate mofetil, and methylprednisolone) compromise the patient's immune system during treatment, and all patients still developed neutralizing antibodies against AAV capsid, precluding future re-administration. Furthermore, many AAV gene therapy clinical trials do not utilize immunosuppression prophylactically and only administer corticosteroids upon signs of inflammation or tissue damage, which has been associated with variable therapeutic efficacy [22, 23]. Interestingly, in agreement with their ability to trigger inflammatory and immune responses, AAV vectors have also been developed as vaccine vehicles against infectious diseases and cancer [39-41].
- Inflammation has been implicated as a critical determinant of successful AAV-mediated transgene expression. A study found that following AAV administration in mice, artificially inducing systemic inflammation such as the upregulation of tumor necrosis factor (TNF), led to a decline in transgene expression in the liver [42]. This indicates that immunological tolerance to AAV-encoded transgene can be broken given sufficient inflammatory responses. Another study characterized inflammation in the murine liver following AAV infection and found transient increases in liver enzymes in the serum, and also liver pathology consistent with portal and lobular inflammation [43]. Strikingly, the authors observed that the use of AAVrh.32.33 viruses, which induced higher liver enzymes than other tested AAV serotypes, also led to a decline in transgene expression to below detection levels, again suggesting that inflammatory and immune responses are associated with poor transgene expression.
- In hemophilia B clinical trials, it has been observed that a subset of patients exhibited elevated liver enzymes, and this transient transaminitis was accompanied by declining levels of transgene-encoded factor IX [22, 23]. A tapering course of corticosteroid therapy was used on a patient with transaminitis, which subsequently normalized aminotransferase levels in the serum and rescued further decline of factor IX expression. Overall, these observations are compatible with immune-mediated destruction of AAV-transduced hepatocytes and demonstrate that inflammatory and immune responses triggered by AAV administration are a safety concern and can hamper therapeutic efficacy in humans. Thus, it would be advantageous to develop viral vectors that intrinsically evade eliciting inflammation. Furthermore, instead of systemic immunosuppression with drugs, it would be beneficial to avoid triggering specific immune responses.
- It has been previously shown that the DNA genome of AAV is sensed by Toll-like receptor 9 (TLR9) during AAV's entry into the cell through the endocytic pathway [36, 44]. TLR9 is a pattern recognition receptor (PRR) found on endosomal membranes of immune cells such as B cells, monocytes, macrophages and plasmacytoid dendritic cells, and binds to unmethylated CpG motifs found in the AAV genome [45, 46]. This leads to TLR9 dimerization, which triggers a cascade of signal transduction that activates NF-kB (also known as p52-RelA complex) and induces type I interferons (IFNs). NF-kB in turn drives the transcriptional upregulation of multiple proinflammatory cytokines such as TNF leading to inflammation and immune cell recruitment, while secreted IFNs induce the expression of numerous interferon-stimulated genes (ISGs) and establish an antiviral state. Importantly, genetic ablation of TLR9 in mice abolishes induction of inflammatory cytokines upon AAV treatment in the liver, and also reduces formation of antibodies and T cells against AAV [36]. Thus, TLR9 plays a critical role in stimulating an early inflammatory and innate immune response during AAV infection, which also contributes to priming adaptive immunity. Finally, two other pattern recognition receptors, TLR2 and TLR4, have been implicated in triggering responses to AAV structural proteins [47, 48].
- In the TLR9 field, a commonly used tool to block TLR9 activation in cell culture is short, single-stranded DNA oligonucleotides that bind TLR9 but do not activate it [49, 50]. Several such sequences are known—some synthetic and others derived from organisms—and they often bear no sequence homology [51-59]. Structural studies have revealed how an inhibitory oligonucleotide binds TLR9 tightly but does not trigger TLR9 dimerization, which is required for TLR9 activation and downstream signaling [60]. In addition to binding TLR9 directly to antagonize its activation, other mechanisms to block TLR9 activation or TLR9-mediated inflammation have been postulated or shown for other TLR9-inhibitory oligonucleotides [reviewed in 49]. These include competing for receptor-mediated endocytosis or phagocytosis, inhibition of TLR9 trafficking or TLR9 processing into a functionally active product, inhibition of endosomal acidification or activity of key proteases in endosomes, or blocking signaling proteins downstream of TLR9. When these inhibitory oligonucleotides are supplied in trans with TLR9 ligands (such as a DNA virus, or a CpG-containing oligonucleotide) in cell culture media, they are endocytosed and can bind to TLR9, preventing its activation by stimulatory ligands. Supplementation of inhibitory oligonucleotides in trans is widely adopted in immunology experiments, but it is unknown in the field if incorporation of these sequences into a viral genome allows it to evade eliciting inflammatory and immune responses.
- While AAV has been shown to elicit much weaker inflammatory responses in comparison to adenoviruses, Glybera™ alipogene tiparvovec treatment still includes twelve weeks of immunosuppression, beginning three days before Glybera™ alipogene tiparvovec administration. These immunosuppressive drugs strongly hamper T cell activation and therefore compromise the patient's immune system during treatment. It would be advantageous to engineer viral vectors that evade and elicit diminished or no inflammatory response upon administration. Furthermore, it would be beneficial if the immune suppression was not systemic, and if it was transient. Preventing inflammatory and immune responses could also improve transgene expression and may allow the re-administration of the viral vector for future purposes.
- There is a continuing need in the art to improve the efficacy of viral vectors for therapy and for in vivo production of biological products.
- According to one aspect of the invention a nucleic acid molecule is provided. It comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- According to another aspect a recombinant virus is provided for delivery of a desired function to a mammalian cell. The recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- Another embodiment is an aspect of treating a mammal. The method comprises administering a recombinant virus to a mammal in need thereof. The recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.
- Still another aspect is a method of making a viral genome of a recombinant virus. An inhibitory nucleic acid sequence is inserted into a viral genome. The inhibitory nucleic acid sequence binds to TLR9 but does not trigger TLR9 activation.
- According to one aspect a nucleic acid molecule is provided. It comprises an inverted terminal repeat (ITR) and a nucleic acid sequence which inhibits TLR9-mediated inflammation.
- Another aspect of the invention is a nucleic acid molecule. The molecule comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.
- Yet another aspect of the invention is a recombinant virus for delivery of a desired function to a mammalian cell. The recombinant virus comprises a viral genome comprising an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.
- Still another aspect of the invention is a method of making a viral genome of a recombinant virus. A nucleic acid sequence is inserted into a viral genome. The nucleic acid sequence inhibits TLR9-mediated inflammation.
- According to another aspect of the invention a nucleic acid vector is provided. The vector comprises at least one nucleic acid sequence. The nucleic acid sequence is capable of inhibiting TLR9-mediated inflammation.
- Another aspect of the invention is a method of reducing immunogenicity of a modified virus having a genome. The method comprises inserting a nucleic acid sequence into the genome. The nucleic acid sequence inhibits TLR9-mediated inflammation. The modified virus causes a reduced inflammatory response in a host as compared to a virus that does not contain the inhibitory sequence.
- Still another aspect of the invention is a method of increasing expression in a host cell of a virally introduced transgene. The method comprises introducing into a host a modified virus having a genome. The genome comprises a nucleic acid sequence. The nucleic acid sequence inhibits TLR9-mediated inflammation. The modified virus results in higher transgene expression in a host cell as compared to a virus that does not contain the inhibitory sequence.
- Yet another aspect of the invention is a composition comprising a viral capsid encapsidating a nucleic acid sequence that inhibits TLR9-mediated inflammation.
- These and other aspects and embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with tools for better treating mammals with viral vectors and virions and for better using viral vectors and virions for producing products of transgenes in host cells, host tissues, and host animals.
- Any and all of the above described aspects may be combined with any of the following features.
- The viral genome may be adeno-associated virus (AAV) genome.
- The viral genome may be selected from the group consisting of adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus,
human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, and human parvovirus B19. - The viral genome may be single stranded.
- The viral genome may be packaged in a virion.
- The viral genome may comprise a gene which may be expressible in a human cell.
- The viral genome may be a cytotoxic virus for lysing target tumor cells.
- The inhibitory nucleic acid sequence may comprise c41 oligonucleotide sequence TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1).
- The inhibitory nucleic acid sequence may comprise a plurality of copies of c41 sequence (SEQ ID NO: 1).
- The inhibitory nucleic acid sequence may comprise two copies of c41 sequence (SEQ ID NO: 1) separated by a linker sequence.
- The linker sequence is AAAAA (SEQ ID NO: 8).
- The inhibitory nucleic acid sequence may be selected from the group consisting of:
-
ODN 2088: (SEQ ID NO: 2) TCC TGG CGG GGA AGT; ODN 4084-F: (SEQ ID NO: 3) CCTGGATGGGAA; ODN INH-1: (SEQ ID NO: 4) CCTGGATGGGAATTCCCATCCAGG; ODN INH-18: (SEQ ID NO: 5) CCT GGA TGG GAA CTT ACC GCT GCA; ODN TTAGGG: (SEQ ID NO: 6) TT AGG GTT AGG GTT AGG GTT AGG G; and G-ODN: (SEQ ID NO: 7) CTC CTA TTG GGG GTT TCC TAT. - The inhibitory nucleic acid sequence may be a bacterial sequence.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human gene.
- The inhibitory nucleic acid sequence may be inserted downstream of or in a 3′ untranslated region of the viral genome.
- The viral genome may be covalently linked to the inhibitory nucleic acid sequence by a phosphodiester bond.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a detectable marker.
- The detectable marker may be inducible.
- The inhibitory nucleic acid sequence may comprise a human telomere sequence shown in SEQ ID NO: 9.
- The viral genome may be self-complementary.
- The viral genome may be covalently linked to a plurality of inhibitory nucleic acid sequences.
- The plurality of inhibitory nucleic acid sequences may comprise an inhibitory sequence and its reverse complement.
- The inhibitory nucleic acid sequence may comprise three copies of c41 sequence (SEQ ID NO: 1), each copy separated by a linker sequence.
- The inhibitory nucleic acid sequence may be selected from the group consisting of:
-
ODN 2114: (SEQ ID NO: 16) TCCTGGAGGGGAAGT; ODN 4024: (SEQ ID NO: 17) TCCTGGATGGGAAGT; ODN INH-4: (SEQ ID NO: 18) TTCCCATCCAGGCCTGGATGGGAA; ODN INH-13: (SEQ ID NO: 19) CTTACCGCTGCACCTGGATGGGAA; ODN Poly-G: (SEQ ID NO: 20) GGGGGGGGGGGGGGGGGGGG; ODN GpG: (SEQ ID NO: 21) TGACTGTGAAGGTTAGAGATGA; ODN IRS-869: (SEQ ID NO: 22) TCCTGGAGGGGTTGT; ODN IRS-954: (SEQ ID NO: 23) TGCTCCTGGAGGGGTTGT; and ODN 21158: (SEQ ID NO: 24) CCTGGCGGGG. - The inhibitory nucleic acid sequence may be ODN TTAGGG (SEQ ID NO: 6).
- The inhibitory sequence may be covalently linked to a linker.
- The inhibitory sequence may be upstream of the linker.
- The inhibitory nucleic acid sequence may comprise a plurality of copies of ODN TTAGGG (SEQ ID NO: 6).
- The plurality of copies of ODN TTAGGG (SEQ ID NO: 6) may each be separated by a linker.
- The inhibitory nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of ODN TTAGGG (SEQ ID NO: 6), each copy separated by a linker.
- The inhibitory nucleic acid sequence may be a human sequence.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human nucleic acid sequence.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human gene.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human nucleic acid sequence.
- The inhibitory nucleic acid sequence may be inserted in the 5′ untranslated region of the viral genome.
- The inhibitory nucleic acid sequence may be inserted upstream of a promoter of the viral genome.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise an inducible promoter.
- The inhibitory nucleic acid sequence may comprise two repeated monomers of SEQ ID NO: 1.
- The inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 1.
- The inhibitory nucleic acid sequence may comprise SEQ ID NO: 6 or SEQ ID NO: 9.
- The inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.
- The inhibitory nucleic acid sequence may comprise five repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.
- The step of administering may be repeated.
- The viral genome may be packaged in virions.
- The step of inserting may utilize a DNA ligase.
- The viral genome may be single stranded when in virions.
- The viral genome of the recombinant virus may comprise a gene for delivery to and expression in a human cell.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a linker separating each of the nucleic acid sequences.
- The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of the nucleic acid sequence.
- The inhibitory nucleic acid may be covalently linked to a gene.
- The inhibitory nucleic acid sequence may be 95% identical to c41 oligonucleotide sequence TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1).
- The inhibitory nucleic acid sequence may be 95% identical to SEQ ID NO: 9.
- The inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:
-
ODN 2088: (SEQ ID NO: 2) TCC TGG CGG GGA AGT; ODN 4084-F: (SEQ ID NO: 3) CCTGGATGGGAA; ODN INH-1: (SEQ ID NO: 4) CCTGGATGGGAATTCCCATCCAGG; ODN INH-18: (SEQ ID NO: 5) CCT GGA TGG GAA CTT ACC GCT GCA; ODN TTAGGG: (SEQ ID NO: 6) TT AGG GTT AGG GTT AGG GTT AGG G; and G-ODN: (SEQ ID NO: 7) CTC CTA TTG GGG GTT TCC TAT. - The inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:
-
ODN 2114: (SEQ ID NO: 16) TCCTGGAGGGGAAGT; ODN 4024: (SEQ ID NO: 17) TCCTGGATGGGAAGT; ODN INH-4: (SEQ ID NO: 18) TTCCCATCCAGGCCTGGATGGGAA; ODN INH-13: (SEQ ID NO: 19) CTTACCGCTGCACCTGGATGGGAA; ODN Poly-G: (SEQ ID NO: 20) GGGGGGGGGGGGGGGGGGGG; ODN GpG: (SEQ ID NO: 21) TGACTGTGAAGGTTAGAGATGA; ODN IRS-869: (SEQ ID NO: 22) TCCTGGAGGGGTTGT; ODN IRS-954: (SEQ ID NO: 23) TGCTCCTGGAGGGGTTGT; and ODN 21158: (SEQ ID NO: 24) CCTGGCGGGG. - The inhibitory nucleic acid sequence may comprise a plurality of copies of SEQ ID NO: 6 and/or SEQ ID NO: 9
- The inhibitory nucleic acid sequence may comprise two copies of SEQ ID NO: 6 and/or SEQ ID NO: 9 separated by a linker sequence.
-
FIG. 1 . Schematic drawing of viral gene therapy and inflammatory and immune responses. -
FIG. 2 . Schematic drawing showing TLR9 sensing AAV DNA during viral entry and inflammatory and immune responses. From Rogers et al., 2011, Frontiers in Microbiology, “Innate Immune Responses to AAV Vectors,” vol. 2, article 194. -
FIGS. 3A-3B .FIG. 3A shows nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide.FIG. 3B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LPA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted inFIG. 3B is shown in SEQ ID NO: 8. -
FIG. 4 shows NF-kB activity in HEK293 TLR9 cells mock-infected or infected with AAV virus (DJ capsid, self-complementary AAV genome, encoding eGFP). **, p<0.005; n.s., not significant. This experiment used a crude viral preparation. -
FIG. 5 . Flow cytometry histograms showing GFP expression in HEK293 TLR9 cells mock-infected or infected with AAV virus with or without c41. This experiment used a crude viral preparation. -
FIGS. 6A-6B .FIG. 6A shows nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG)4 (SEQ ID NO: 6) motif from mammalian telomeres.FIG. 6B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown inFIG. 6B are SEQ ID NO: 8. -
FIGS. 7A-7B .FIG. 7A shows the percentage of transduced cells (GFP+) 2 days after infection of a B cell line with similar amounts of indicated AAV viruses, analyzed by flow cytometry.FIG. 7B shows TNF production in the supernatant of primaryhuman CD14+ monocytes 18 hours after infection, as assayed by ELISA. -
FIG. 8A-8B . Engineering a self-complementary AAV vector. (FIG. 8A ) DNA sequences of “c41” and “telomere”. (FIG. 8B ) Genome organization of an AAV vector (scAAV-eGFP) and modified vectors. LpA: polyA signal. -
FIG. 9A-9C Inflammatory response to various AAV vectors in human immune cells in vitro. (FIG. 9A ) Primary human macrophages were infected with AAV2 viruses (MOI: 105 vg/cell) and supernatants were collected 18 h later and analyzed by ELISA for TNF levels. FiveuM ODN 2006, a CpG-containing oligonucleotide, served as a positive control. (FIG. 9B ,FIG. 9C ) Primary human CD14+ monocytes from two different donors were infected similar to (A) and analyzed for TNF levels. Data shown are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP. -
FIG. 10A-10E . Further characterization of AAV vectors. (FIG. 10A ) DNA sequence of “control”. (FIG. 10B ) Genome organization of modified vectors. (FIG. 10C ) Primary human macrophages were infected with AAV2 viruses similar to (FIG. 9A ) and analyzed by ELISA for TNF levels. (FIG. 10D ) Primary human monocytes were infected similar to (FIG. 9B ,FIG. 9C ) and analyzed by ELISA for TNF levels. Data shown (FIG. 10C ,FIG. 10D ) are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP. (FIG. 10E ) Adult C57BL/6 mice were infected with indicated AAV2 viruses similar to (FIG. 12A ,FIG. 12B andFIG. 12C ) and a piece of the liver was analyzed for indicated gene expression by qRT-PCR. Data shown are mean±s.d. of n=5 mice per condition except n=3 mice for scAAV-eGFP-3×control. *P<0.05 (unpaired t-test) compared to saline condition. N.s.: not significant (P>0.05). -
FIG. 11A-11B . (FIG. 11A ) Primary human macrophages using a different lot of both AAV2 viruses were infected similar to (FIG. 9A ) and analyzed for TNF levels. (FIG. 11B ) HeLa cells were infected with AAV2 viruses at indicated MOIs and cells were harvested 48 h later and analyzed by flow cytometry for GFP expression. The percentage of GFP positive cells are shown Data shown are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP. -
FIG. 12A-12C Inflammatory response to intravenous administration of various AAV vectors in adult mice in vivo. (FIG. 12A ,FIG. 12B andFIG. 12C ) Adult C57BL/6 mice were infected with indicated AAV2 viruses (1011 vg per mouse) by tail vein injections. 2 h later, the animals were euthanized and a piece of the liver was analyzed for indicated gene expression by qRT-PCR. Saline injection was set to 1-fold expression for each gene. Data shown are mean±s.d. of n=3 mice per condition (FIG. 12A ) or n=4 mice per condition (FIG. 12B andFIG. 12C ). *P<0.05 (unpaired t-test) compared to saline condition. N.s.: not significant (P>0.05). -
FIG. 13 . Genome organization of a single-stranded AAV vector (ssAAV-eGFP) and ssAAV-eGFP-5× telomere. -
FIG. 14A-14C . Inflammatory and immune response following subretinal administration of various AAV vectors in neonatal mice in vivo. (FIG. 14A ,FIG. 14B andFIG. 14C ) Neonatal CD1 mice (P1) received indicated AAV8 viruses (1.8×108 vg per mouse eye) by subretinal injections. At P21, the animals were euthanized and the eyecup was dissected out. The retina and the rest of the eyecup were analyzed for indicated gene expression by qRT-PCR. Saline injection was set to 1 fold expression for each gene. Each triangle represents an animal. Data shown are n=3 mice (saline) and n=5 mice (each virus) and mean values are indicated. -
FIG. 15A-15C . Analysis of immune cell markers in the retina following subretinal administration of various AAV vectors in neonatal mice in vivo. (FIG. 15A ,FIG. 15B andFIG. 15C ) Similar to (FIG. 14A-14C ), the retina was analyzed for indicated gene expression by qRT-PCR. Aif1 (Iba1) is known to be expressed in microglia, while Cd4 and Cd8a are markers of helper and cytolytic T cells respectively. Saline injection was set to 1 fold expression for each gene. Each triangle represents an animal. Data shown are n=3 mice (saline) and n=5 mice (each virus) and mean values are indicated. -
FIG. 16 . GFP expression in the eye. Neonatal CD1 mice (P1) received indicated AAV8 viruses (1.8×108 vg per mouse eye) by subretinal injections. At P30, the animals were euthanized and GFP expression was visualized in flat-mounted eye cups. Data shown are n=2 mice per condition. -
FIGS. 17A-17B .FIG. 17A shows nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide.FIG. 17B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LPA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted inFIG. 17B is shown in SEQ ID NO: 8. -
FIGS. 18A-18B .FIG. 18A shows nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG)4 (SEQ ID NO: 6) motif from mammalian telomeres.FIG. 18B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown inFIG. 18B are SEQ ID NO: 8. - The inventors have developed viral vectors and virions that harbor their own protection against host immune and inflammatory systems. These vectors and virions carry short nucleic acid sequences which inhibit the activation of toll-like receptor 9 (TLR9), a host protein which activates inflammatory and immune responses in mammalian cells.
- A short nucleotide sequence for inhibition of TLR9 may be of any origin. It can be bacterial, human, synthetic, or from other sources. One particular sequence is the 20 nucleotide long “c41” [TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1)] from Pseudomonas aeruginosa. Another particular sequence is from human telomeres and comprises (TTAGGG)4 (SEQ ID NO:6). Other inhibitory sequences are shown in SEQ ID NO: 2-5, 7, 9, and 16-24. Inhibitory sequences may also be used which share at least 80% homology/identity with these sequences. Inhibitory sequences may also be used which share at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and/or at least 99% homology/identity with these sequences. Multiple copies of the inhibitory sequence can be used, either in tandem arrays or separated in the viral vector by spacer or linker sequences or other portions of the viral genome. In some embodiments one, two, three, four, five, six, seven, eight, nine, ten, fifteen, or twenty copies are used. In some embodiments one or more copies of the inhibitory sequence are on the plus strand and some on the minus strand of the virus genome.
- The inhibitory oligonucleotide sequences are introduced into host cells as part of the viral genome or virion, rather than as a separate agent. This renders the effect of the oligonucleotide sequences local rather than systemic. Moreover, the immune evasion is transient as it occurs during AAV or other virus entry, unlike immune suppression with drugs which can last for weeks. Additionally, it ensures that the beneficial antagonist activity is where it needs to be—with the virus or viral genome. If the virus or viral genome is not replicated in the host cell, then the effect of the oligonucleotide will be transient. If the virus or viral genome is replicated, the effect will be coextensive with the replication.
- An inhibitory nucleic acid sequence may be inserted into a viral genome using any means of recombinant DNA engineering. This may involve in vitro or in vivo recombination. In vitro recombination may be accomplished using a DNA ligase or other nucleic acid joining enzyme, for example. In vivo recombination may be accomplished by co-transforming a host cell with separate donor molecules that share homology by which they will recombine using host cell machinery. Alternatively, a single donor molecule may recombine in vivo with a host cell sequence. Combinations of these approaches may also be used. Typically the insertion will involve a standard linkage of one deoxyribonucleotide to another (a phosphodiester bond). However, there may be circumstances in which non-standard linkages will be used between the inhibitory nucleic acid sequence and the rest of the viral genome. Optionally, the inhibitory nucleic acid sequence is located in an untranslated region of the viral genome.
- The genome may optionally contain a therapeutic gene and/or a marker gene. Typically this gene will be a non-viral gene, or a gene that is not naturally present in the viral genome. The gene may be expressible in a mammalian host cell or animal. Expression may be under the control of a viral promoter or a promoter that is introduced with the gene. Expression may be inducible, repressible, condition-responsive, or constitutive, as examples. A therapeutic gene is one which encodes an RNA or protein product beneficial to the host. The benefit may be, for example, to improve health, protect against infection, or remedy a deficiency. The marker may enable one to track the location, the level of replication, the level of propagation, the level of transcription, or the level of translation of the virus or its products or components. Suitable markers include those which are readily detectable, such as fluorescent proteins, chromogenic proteins, etc. Optionally, a second agent may be used or added for detection of the marker protein or for development of a detectable substance. Introduced genes may be human or non-human, heterologous (from another species) or homologous (from same species) or endogenous (from the same subject).
- Any DNA viral genome can be used, whether single stranded or double stranded. Examples of suitable viruses which may be used, include without limitation, wild-type or variants of adeno-associated virus (AAV), adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus,
human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, human parvovirus B19, and enterovirus. The virus may be, without limitation, cytotoxic, cytolytic, or cause latent infections. Viral vectors in which viral genomes have been modified may also be used. As an example, a genome that is modified to encode fewer viral proteins may be used. As a further example, a viral genome that is modified to encode no viral proteins may be used. Viral genomes may include, by way of non-limiting example, inverted terminal repeats and/or other non-coding genetic elements that facilitate packaging of engineered viral genomes into the capsid. - Viral genomes may be delivered to a mammalian host cell as naked DNA, in a liposome, complexed to a polymer, in a condensed or compacted state, in a gold particle, in a virion, or any other means that is suitable for the application. Typically a complete viral genome will be administered, but in some situations, it may be desirable to use a partial genome. The partial genome may be complemented by helper functions provided by the host cell or another genomic or viral entity. Partial genomes may be used, for example, if the therapeutic payload is large and some essential viral functions must be omitted to package.
- Recombinant viruses may be administered to a mammal or mammalian cells according to any route which is effective for the purpose. The administration may be systemic, e.g., via the blood. It may be delivered orally, subcutaneously, topically, bucally, anally, intramuscularly, intravenously, intratumorally, intracranially, intrathecally, subretinally, etc. Any suitable carrier or vehicle may also be used for administration. It may be desirable to pre-treat the cells or mammal to render them more permeable to or receptive to the recombinant virus. A mammal “in need of” a recombinant virus may be one for whom the virus will be beneficial. It may be a mammal with a disease or deficiency. It may be one for whom a diagnosis or analysis will be made. It may be one who can benefit from the administered recombinant virus, even though it does not have a disease or deficiency.
- Taken together, our results show that incorporation of c41 or human telomeric sequences into the AAV genome (a) does not lower viral packaging and infectivity, (b) prevents TLR9-mediated inflammation, (c) reduces induction of pro-inflammatory cytokines, and (d) increases transgene expression. The increased transgene expression may be due to a reduced immune response, as TLR9 activation also induces interferon expression, which triggers an antiviral state. The engineered immune-evasion property we show below is specific (against TLR9), transient (e.g., may occur during viral entry), and does not result in systemic immune suppression (only targets AAV-infected immune cells).
- The inhibitory nucleic acid sequences we used, as well as others known in the art, may be incorporated into other viruses that, like AAV, have potential utility for humans and other mammals but elicit inflammatory/immune responses that may be undesirable. For example, oncolytic viruses that preferentially infect and lyse cancer cells are used to kill or shrink tumors. These viruses are replicative (unlike AAV vectors used for gene therapy) so they can release new virions to shrink the remaining tumor. Examples include wild-type or variants of herpes simplex virus, adenovirus, and enterovirus. Some reports have shown that immunosuppression by chemotherapy can enhance oncolytic virus therapy, as the immune system normally attempts to inactivate the oncolytic virus, which would prevent it from infecting cancer cells. Therefore, it is possible that incorporating inhibitory oligonucleotides in the genomes of oncolytic viruses like herpes simplex virus may allow it to evade immune clearance and persist longer for oncolysis.
- The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. The disclosure of the invention includes all embodiments explicitly recited in the claims. Additionally, all features disclosed in the dependent claims apply equally to the independent claim from which they are based as to the other independent claims. Thus such combinations of dependent claims with other independent claims are expressly contemplated and disclosed.
- To engineer an AAV vector that has the ability to specifically evade TLR9 activation in immune cells, we inserted two copies of c41 separated by a 5-nucleotide-long spacer (AAAAA; SEQ ID NO: 8) into the 3′ untranslated region of AAV vector encoding enhanced green fluorescent protein (eGFP) (
FIG. 3B ). Subsequently, we produced wild-type AAV-eGFP virus and AAV-eGFP-c41 virus (harboring two c41 insertions). Infectious titers of both viruses were comparable (˜109 infectious units/ml, as determined by titering on HeLa cells), suggesting that addition of c41 into the viral genome did not hamper viral packaging and infectivity, an important consideration for viral vectors that have to be mass-produced for gene therapy. - To measure the inflammatory response, we used HEK293 cells stably expressing TLR9 (HEK293 TLR9 cells), which senses AAV DNA genomes, and also expressing alkaline phosphatase under the transcriptional control of NF-kB. When NF-kB is activated, which indicates inflammation, alkaline phosphatase is secreted into the media and acts on a provided substrate, leading to a change in color of the media that can be measured on a plate reader. We mock-infected HEK293 TLR9 cells or infected them with either AAV-eGFP or AAV-eGFP-c41. In agreement with the literature, AAV-eGFP infection induced a small but statistically significant increase in NF-kB activity (
FIG. 4 ). In contrast, AAV-eGFP-c41 infection was not significantly different compared to mock-infected cells, indicating that the virus was able to evade eliciting an inflammatory response. - We analyzed the above three conditions (described in
FIG. 4 ) for eGFP expression using flow cytometry. We found that AAV-eGFP-c41 transduced more cells than AAV-eGFP (52.7% GFP+ compared to 34.6% GFP+) (FIG. 5 ). In addition, GFP+ cells from AAV-eGFP-c41 infection expressed ˜twice as much eGFP as GFP+ cells from AAV-eGFP infection (mean fluorescence intensity [MFI] of 5335 compared to 2749). - In summary, we engineered an AAV vector to evade TLR9-mediated inflammation by incorporating an inhibitory oligonucleotide in the viral genome.
- We inserted three copies of “telomere,” a sequence derived from mammalian telomeres that contains the suppressive (TTAGGG)4 motif (SEQ ID NO: 6), which has been shown to block TLR9 signaling (
FIG. 6A andFIG. 6B ). AAV-eGFP-telomere virus yielded similar viral titers as AAV-eGFP and AAV-eGFP-c41 when titered on HeLa cells, demonstrating that incorporation of “telomere” does not hinder viral packaging and infectivity. - When we infected a B cell line with similar amounts of AAV-eGFP or AAV-eGFP-c41 or AAV-eGFP-telomere virus, both AAV-eGFP-c41 and AAV-eGFP-telomere viruses transduced more cells than AAV-eGFP (
FIG. 7A ). This finding suggests too that incorporation of inhibitory sequences in the genome of AAV increases transgene expression. - Subsequently, we harvested primary human CD14+ monocytes from blood and subjected them to similar infection conditions as above. We performed ELISA on the supernatant to analyze TNF production, as TNF is a prototypical pro-inflammatory cytokine induced by NF-kB activation. AAV-eGFP infection increased TNF production compared to mock-infection, while AAV-eGFP-c41 and AAV-eGFP-telomere infections showed no or little increase in TNF production (
FIGS. 7A-7B ), showing that the two viruses were able to evade eliciting inflammatory responses. - Investigators often use short inhibitory oligonucleotides (typically 10-30 nucleotides in length) to antagonize TLR9 signaling in cell culture. However, it is unknown if these inhibitory oligonucleotides retain functionality in the context of a much larger viral genome (i.e., the sequence is covalently linked on both ends to much longer sequences). To test this possibility, we utilized a self-complementary (sc) AAV vector encoding enhanced green fluorescent protein (eGFP), and inserted 3 copies of “c41” or “telomere”, derived from bacteria and mammalian telomeres respectively [52, 57, 58, 61], into a plasmid harboring the vector genome (
FIGS. 8A and 8B ). We started with sc AAV vectors as they have been shown to be more efficient at triggering TLR9 activation and inducing more inflammation in the mouse liver than single-stranded (ss) AAV vectors. As “c41” and “telomere” are predicted to have strong secondary structure, we used an AAAAA linker between copies of the inhibitory oligonucleotide. In addition, 3×c41 and 3× telomere sequences were placed after the polyA sequence and upstream of the right inverted terminal repeat (ITR) so they would be present in the DNA genome during viral entry, but would be absent from subsequent mRNA transcripts upon successful transduction (“scAAV-eGFP-3×c41” and “scAAV-eGFP-3× telomere”). Finally, to determine if the location of inhibitory oligonucleotide in the viral genome matters, we also created a vector where 3× telomere was located between the left ITR and the promoter (“scAAV-3× telomere-eGFP”). - We packaged the various AAV vectors into AAV2 serotype and infected primary human monocyte-derived macrophages at a multiplicity of infection (MOI) of 105 viral genomes (vg) per cell. As expected, we found that scAAV-eGFP infection of macrophages elicited robust induction of TNF in the supernatant, a prototypical inflammatory cytokine with well-described roles in stimulating fever, apoptosis and inflammation, and is produced upon TLR9 signaling and NF-kB activation (
FIG. 9A ). In contrast, both scAAV-eGFP-3×41 and scAAV-eGFP-3× telomere markedly decreased TNF induction by >95%, indicating that incorporation of “c41” or “telomere” in these viruses could evade eliciting inflammatory responses compared to the wild-type (WT) vector. Furthermore, scAAV-3× telomere-eGFP was also able to prevent TNF induction by >95%, demonstrating that the inserted inhibitory oligonucleotides can be placed in other parts of the viral genome and retain the ability to block inflammation. Mock infection with phosphate-buffered saline (PBS) and treatment withODN 2006, a commercially available CpG-containing oligonucleotide that is known to strongly activate TLR9/NF-kB and inflammation, served as negative and positive controls respectively. We tested primary human CD14+ monocytes and found that again, scAAV-eGFP triggered robust TNF induction while scAAV-eGFP-3×c41 and scAAV-eGFP-3× telomere negated most of the TNF induction (FIG. 9B ). scAAV-3× telomere-eGFP likewise reduced TNF induction, although inhibition was ˜85%, which may be due to differences between cell types or donor tissue. The evasion of TNF induction was also reproduced in primary CD14+ monocytes obtained from another donor (FIG. 9C ). - As further characterization, we inserted 3 copies of “control,” a random sequence that does not block TLR9, or 1 copy of “telomere”, into a plasmid harboring the vector genome (
FIG. 10A ,FIG. 10B ). We picked the sequence “control” as it has been used as a negative control oligonucleotide in TLR9 experiments. We found that scAAV-eGFP-lx telomere was able to reduce TNF induction compared to scAAV-eGFP in human macrophages, but not as efficiently as scAAV-eGFP-3× telomere (FIG. 10C ). This indicates that 1 copy of telomere can reduce inflammation. We also observed that scAAV-eGFP-3×control elicited TNF secretion as efficiently as scAAV-eGFP in human monocytes, suggesting that insertion of sequences that inhibit TLR9 are required to block inflammation (FIG. 10D ). - As AAV vectors are considered biologics and may exhibit lot-to-lot variability, we produced another batch of both scAAV-eGFP and scAAV-eGFP-3× telomere AAV2 viruses, and found that scAAV-eGFP-3× telomere was able to reduce ˜75% of TNF induction compared to the WT vector (
FIG. 11A ). Based on the multiple viral preps and donor monocytes and macrophages (FIGS. 9A-9C ,FIGS. 10A-10E andFIGS. 11A-11B ), we conclude that our engineered vectors containing 3 copies of “c41” or “telomere” reduce TNF induction by approximately 75-98% compared to the WT vector. On average, scAAV-eGFP-3× telomere reduced ˜85% of TNF induction compared to scAAV-eGFP. Importantly, we did not observe differences in viral titers (assayed by qPCR for viral genomes) obtained from producing any of the above AAV2 vectors, suggesting that the engineered vectors are not defective in packaging (data not shown). Furthermore, when we infected HeLa cells, a permissive cell line widely used to titer AAV infectivity, with a range of MOIs of scAAV-eGFP and scAAV-eGFP-3× telomere, we did not observe differences in transduction (% GFP+ cells) over 4 logs of viral titers, demonstrating that the engineered vector is equally competent at transducing cells (FIG. 11B ). - Intravenous delivery of AAV is often used to transduce hepatocytes for gene therapy. Previous work has shown that upon intravenous administration of AAV, Kupffer cells (resident hepatic antigen-presenting cells) in the liver of mice are capable of sensing sc AAV genomes and triggering inflammatory and innate immune responses 1-9 h later [36]. These responses include induction of proinflammatory cytokines such as TNF and IL6 and type I interferons such as IFN-β. TLR9−/− mice do not exhibit these inflammatory and innate immune responses in the liver, demonstrating a central role for TLR9 in vivo as an innate immune sensor. In addition, immune cells such as neutrophils, macrophages and natural killer (NK) cells infiltrate the liver 2 h after AAV administration. To determine if our engineered vectors can reduce inflammation in the liver in vivo, we administered PBS or equal amounts of scAAV-eGFP or scAAV-eGFP-3× telomere via tail vein injection. We selected scAAV-eGFP-3× telomere for in vivo characterization as “telomere” is derived from human sequences and might be preferable for clinical use. In agreement with previous work, scAAV-eGFP stimulated increased Tnf and 116 expression in the liver (approximately 3 to 10 fold, compared to saline), indicating inflammation (
FIG. 12A ). In contrast, scAAV-eGFP-3× telomere showed little to no increase in inflammatory markers. We tested more mice in subsequent experiments and found that scAAV-eGFP stimulated statistically significant Tnf induction in the liver compared to saline, while scAAV-eGFP-3× telomere and scAAV-eGFP-3×c41 did not (FIGS. 12B and 12C ), demonstrating their ability to evade eliciting inflammation in the liver. Finally, we confirmed that scAAV-eGFP-3×control is not able to prevent inflammation in the liver compared to scAAV-eGFP (FIG. 10E ). - Next, we engineered a single-stranded AAV vector, ssAAV-eGFP, by inserting 5 copies of “telomere” with AAAAA linkers, followed by another 5 copies but in anti-sense orientation, into the plasmid, giving ssAAV-eGFP-5× telomere (
FIG. 13 ). Since both positive and negative strands of the viral genome are equally likely to be packaged into a viral particle, this ensures that each packaged viral genome would have 5 copies of “telomere” in the correct orientation. Two AAV8 viruses were produced and purified. Again, we did not observe differences in titers between the two vectors, suggesting similar packaging efficiency (data not shown). ssAAV-eGFP was selected as it has been previously used for subretinal injections in mice and efficiently transduces photoreceptors in the eye [62]. - Several studies have suggested that AAV gene therapy in the eye and brain appears to be generally safe [63]. While the eye is often assumed to be an immune-privileged site, it is known to harbor microglia, resident macrophages of the central nervous system which have been reported to express TLR9 and respond to CpG motifs [64-67]. A recent study delivering AAV vectors by subretinal injection in cynomolgus macaques reported dose-related anterior and posterior segment inflammation in the animals, and a macaque was euthanized prematurely due to severe ocular inflammation [68]. Furthermore, vitreous aspirate from the euthanized animal demonstrated the presence of neutrophils and macrophages. Another study utilizing canine models similarly observed anterior and posterior uvetitis upon subretinal injection of AAV vectors, and 3 of 17 eyes developed a multifocal chorioretinitis, which was likewise associated with higher vector doses [69]. These findings strongly suggest that AAV vectors are subject to innate immune surveillance in the eye and can trigger deleterious inflammatory and immune responses.
- Saline or similar amounts of ssAAV-eGFP or ss-AAV-eGFP-5× telomere were delivered via subretinal injection into neonates eyes and measured the expression of inflammatory and immune genes. The three mice that received saline injections were uniformly low for Tnf expression in the retina and were set to 1 fold expression (
FIG. 14A ). In contrast, of the five mice that received ssAAV-eGFP, two exhibited mild upregulation of Tnf (1.9 fold and 8.3 fold), while three animals demonstrated large induction of Tnf (62.2 fold, 534 fold, and 1003 fold), with a mean of 321 fold for the five animals. This finding indicates that while there is variability in inflammation, some animals mount a very strong inflammatory response in the retina upon ssAAV-eGFP subretinal injection. The variability may be due to differences in each injection procedure or the immune status of each animal. Strikingly, the five animals receiving ssAAV-eGFP-5× telomere had a mean Tnf induction of 5.6 fold with much less variability, suggesting that ssAAV-eGFP-5× telomere was able to avoid eliciting strong inflammation. Similar results were observed in the rest of the eyecup but at a lower magnitude, indicating inflammation was not restricted to the retina (FIG. 14B ). We also measured Ifng expression in the retina, a type II interferon critical for antiviral immune responses [70], and observed a similar pattern (FIG. 14C ). Prior studies have suggested that subretinal injection of AAV may trigger immune cell infiltration in the eye. Therefore, we also analyzed expression of genes that are known to be expressed specifically in different types of immune cells. We found 18.2 fold higher expression of Aif1 (encoding Iba1, a specific marker for microglia [71, 72]) in ssAAV-eGFP injections compared to saline, suggesting microglia proliferation and/or activation in the retina (FIG. 15A ). In contrast, ssAAV-eGFP-5× telomere only showed 1.9 fold induction of Aif1 expression. In addition, we found 45.8 fold and 41.8 fold induction of Cd4 and Cd8a, markers of CD4+ helper T cells and CD8+ cytolytic T cells respectively, by ssAAV-eGFP, while ssAAV-eGFP-5× telomere only showed 1.5 fold and 3.4 fold induction (FIGS. 15B and 15C ). Again, there was considerable variability among mice treated with ssAAV-eGFP with a subset of animals showing robust induction. These results demonstrate that subretinal injection of ssAAV-eGFP administration can stimulate T cells infiltration in the retina, while ssAAV-eGFP-5× telomere strongly diminishes it. Taken together, our data indicate that while ssAAV-eGFP induces robust inflammatory and immune responses in the retina and the surrounding tissue, and significant variability is observed, ssAAV-eGFP-5× telomere is capable of mitigating a large portion of these responses. - Given the marked differences in inflammation both in vitro and in vivo, we sought to determine if there are any differences in long-term gene expression. We examined flat-mounted eye cups at P30, 29 d after subretinal injection of the mice, and found that more cells were GFP+ and GFP expression was stronger in ssAAV-eGFP-5× telomere treated eyes compared to ssAAV-eGFP, suggesting enhanced gene expression (
FIG. 16 ). Thus, the engineered vector is able to reduce inflammatory and immune responses in the retina and also augment transgene expression. - C57BL/6 mice (male, 7-9 weeks old) were purchased from the Jackson Laboratory and CD1 mice were purchased from Charles River Laboratories.
- Self-complementary (sc) or single-stranded (ss) AAV vectors were used in this study. Self-complementary vectors lack the terminal resolution sequence in one ITR. All vector genomes were flanked by AAV2 ITRs. scAAV-eGFP was purchased from Cell Biolabs (VPK-430) and has been previously described [73]. scAAV-eGFP expressed enhanced green fluorescent protein (eGFP) from the cytomegalovirus (CMV) promoter, and included an SV40 intron and SV40 polyA sequence. ssAAV-eGFP has been previously described [62] and was originally obtained from the Harvard DF/HCC DNA Resource Core (clone ID: EvN000061595). ssAAV-eGFP contained a CMV enhancer/promoter, human β-globin intron, eGFP, and β-globin polyA sequence. The sequences of “c41” (5′-TGGCGCGCACCCACGGCCTG-3′; SEQ ID NO: 1) derived from Pseudomonas aeruginosa and “telomere” (5′-TTTAGGGTTAGGGTTAGGGTTAGGG-3′; SEQ ID NO: 9; initial T nucleotide is optional for function) derived from mammalian telomeres have been described [52, 57, 58, 61]. A widely used “telomere” oligonucleotide (manufactured by Invivogen, catalog code “tlrl-ttag”) harbored an additional T (in bold) compared to published studies and thus was included in the sequence. During the course of this study, Invivogen removed the additional T in their manufactured “telomere” oligonucleotide (catalog code “tlrl-ttag151”). In addition, “control” (5′-GCTAGATGTTAGCGT-3′; SEQ ID NO: 34) was used as a negative control sequence that does not inhibit TLR9 activation (Invivogen, catalog code “tlrl-2088c”).
- To engineer scAAV-eGFP, sequences were inserted into the unique SpeI site found immediately 5′ of the right ITR. To facilitate sub-cloning, a unique ClaI site was created immediately 5′ of the inserted sequences, thus allowing ClaI/SpeI sub-cloning of sequences. 3 copies of “c41,” “telomere,” or “control” were inserted, separated by AAAAA linkers, giving scAAV-eGFP-3×c41, scAAV-eGFP-3× telomere and scAAV-eGFP-3× control, respectively. Alternatively, one copy of “telomere” was inserted, with an AAAAA linker (SEQ ID NO: 8), giving scAAV-eGFP-lx telomere. We also inserted 3× telomere between the left ITR and CMV promoter using the unique AvrII site, giving scAAV-3× telomere-eGFP.
- To engineer ssAAV-eGFP, KpnI-5× telomere(sense)-5× telomere(anti-sense)-NheI was inserted immediately 5′ of the XbaI site adjacent to the right ITR. Again, AAAAA was used as a linker between copies of “telomere”. Both sense and anti-sense sequences of “telomere” were added as single-stranded AAV vectors have an equal chance of packaging positive or negative strands of the viral genome, thus ensuring that all packaged AAV genomes will carry 5 copies of “telomere” in the right orientation.
- Self-complementary vectors were packaged into AAV2 (Vigene Biosciences) by triple transfection of HEK293 cells and purified using iodixanol gradient ultracentrifugation and then concentrated to 500 ul using Amicon Ultra-15 columns in PBS. The purified viruses were titered by qPCR using primers derived from ITR and an AAV standard. The final yield of the viruses ranged from 0.5-3×1013 vg.
- Single-stranded vectors were packaged into AAV8 based on previously described protocols [74, 75]. Briefly, AAV vector, rep2-cap8 packaging plasmid and adenoviral helper plasmid were transfected into HEK293T cells with polyethylenimine and supernatant was collected 72 h after transfection. AAV8 viruses were precipitated with 8.5% w/v PEG8000 and 0.4M NaCl and centrifuged at 7000 g. The pellet was resuspended in lysis buffer (150 mM NaCl and 20 mM Tris, pH 8.0) and MgCl2 was added to a final concentration of 1 mM. The resuspended viruses were incubated with 25 U/ml Benzonase (Sigma) at 37° C. for 15 min and run on an iodixanol gradient. Recovered AAV vectors were washed 3 times with PBS using Amicon 100K columns (EMD Millipore) and concentrated to 100-500 ul of PBS. Protein gels were run to determine virus titers, using serial dilutions of previous AAV standards for comparison.
- Human peripheral blood mononuclear cells (PBMCs) from unidentified healthy donors were purchased (ZenBio). This study was done in accordance with the ethical guidelines of Harvard Medical School. CD14+ monocytes were positively selected from PBMCs using anti-CD14 magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec) or purchased from Stemcell Technologies. To obtain monocyte-derived macrophages, monocytes were cultured with 50 ng/ml of recombinant human macrophage colony stimulation factor (rhM-CSF, purchased from Peprotech) for 5 to 6 d to allow differentiation into macrophages. Monocytes and macrophages were either used fresh or cryopreserved for subsequent studies.
- 1×105 monocytes or macrophages were seeded in 190 ul of RPMI growth media per well in 96 well round bottom plates or 96 well flat bottom plates respectively, and infected with 10 ul AAV2 viruses at indicated MOIs in PBS. Mock infection (addition of 10 ul PBS) and ODN 2006 (final concentration of 5 uM, Invivogen), a CpG-containing oligonucleotide known to activate TLR9 and trigger inflammation, served as negative and positive controls. 18 h after infection, supernatants were collected and clarified by low speed centrifugation, followed by ELISA for human TNF (Thermo Scientific).
- HeLa cells are highly permissive for AAV2 vectors and are commonly used to determine the transducing titer of AAV2 vector preparations [76]. Briefly, HeLa cells were seeded overnight in 12 wells and were approximately 80% confluent at time of infection (3×105 cells). Cells were infected with serial ten-fold dilutions of viruses at indicated MOIs and incubated for 48 h before fixing with 1% paraformaldehyde in PBS and followed by flow cytometry analysis for GFP+ cells. PBS mock-infected cells were used to determine GFP+ signal.
- Adult C57BL/6 mice were injected intravenously with 100 ul PBS or AAV2 viruses (1011 vg per animal) by tail vein injection as previously described [36]. 2 h later, the animals were sacrificed and a portion of the right median lobe of the liver was saved in RNAlater solution (Thermo Scientific). Total RNA was extracted from 10-30 mg of mechanically disrupted liver sample by using an RNA extraction kit (OMEGA Bio-Tek). Similar amounts of RNA were reverse transcribed into cDNA with a high-capacity RNA-to-cDNA kit (Thermo Scientific) and similar amounts of cDNA were assayed with quantitative PCR (qPCR) using TaqMan Fast Advanced Master Mix (Thermo Scientific) and commercially available pre-designed primers/probes with FAM reporter dye for the indicated target genes (IDT). Expression level for each gene was calculated by normalizing against the housekeeping genes Actb or Gapdh using the AACT method and expressed as fold levels compared to saline-injected mice. All qPCR reactions were run on a realplex4 Mastercycle (Eppendorf).
- Subretinal injection into postnatal day 1 (P1) CD1 neonate eyes were performed as previously described [74, 75]. Approximately 0.2 ul AAV8 virus (1.8×108 vg per eye) was introduced into the subretinal space using a pulled angled glass pipette controlled by a FemtoJet (Eppendorf). At P21, animals were sacrificed and the eyecup was dissected out. The retina and the rest of the eyecup were subjected to RNA extraction, reverse transcription, and qPCR as described in the liver studies. To visualize GFP expression by histology, eyes were excised at P30, fixed in 4% paraformaldehyde for 2 h, and washed in
PBS 3 times. Eye cups were dissected out by removing the cornea, lens, iris, vitreous body and peripheral muscles. Images of flat-mounted eye cups were taken using a ×10 objective on a Keyence BZ-x700 microscope. Images used for comparison between groups were taken at the same imaging settings in the same imaging session. - Unpaired two-tailed Student's t-tests were used to compare differences between two unpaired experimental groups in all cases. A P value of <0.05 was considered statistically significant. No pre-specified effect size was assumed and in general three to five replicates for each condition was used.
-
- 1. Naldini L. Gene therapy returns to centre stage. Nature. 2015; 526(7573):351-60. doi: 10.1038/nature15818. PubMed PMID: 26469046.
- 2. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012; 20(10):1831-2. doi: 10.1038/mt.2012.194. PubMed PMID: 23023051; PubMed Central PMCID: PMCPMC3464639.
- 3. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012; 23(4):310-20. doi: 10.1097/MOL.0b013e3283555a7e. PubMed PMID: 22691709.
- 4. Samulski R J, Muzyczka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol. 2014; 1(1):427-51. doi: 10.1146/annurev-virology-031413-085355. PubMed PMID: 26958729.
- 5. Mingozzi F, High K A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011; 12(5):341-55. doi: 10.1038/nrg2988. PubMed PMID: 21499295.
- 6. Kotterman M A, Schaffer D V. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014; 15(7):445-51. doi: 10.1038/nrg3742. PubMed PMID: 24840552; PubMed Central PMCID: PMCPMC4393649.
- 7. McLaughlin S K, Collis P, Hermonat P L, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol. 1988; 62(6):1963-73. PubMed PMID: 2835501; PubMed Central PMCID: PMCPMC253280.
- 8. Hauswirth W W, Berns K I. Origin and termination of adeno-associated virus DNA replication. Virology. 1977; 78(2):488-99. PubMed PMID: 867815.
- 9. Zhong L, Zhou X, Li Y, Qing K, Xiao X, Samulski R J, et al. Single-polarity recombinant adeno-associated
virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther. 2008; 16(2):290-5. doi: 10.1038/sj.mt.6300376. PubMed PMID: 18087261. - 10. Zhou X, Zeng X, Fan Z, Li C, McCown T, Samulski R J, et al. Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Mol Ther. 2008; 16(3):494-9. doi: 10.1038/sj.mt.6300397. PubMed PMID: 18180769.
- 11. Samulski R J, Chang L S, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 1987; 61(10):3096-101. PubMed PMID: 3041032; PubMed Central PMCID: PMCPMC255885.
- 12. McCarty D M. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008; 16(10):1648-56. doi: 10.1038/mt.2008.171. PubMed PMID: 18682697.
- 13. McCarty D M, Monahan P E, Samulski R J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001; 8(16):1248-54. doi: 10.1038/sj.gt.3301514. PubMed PMID: 11509958.
- 14. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. 2011; 18(9):1586-8. doi: 10.1128/CVI.05107-11. PubMed PMID: 21775517; PubMed Central PMCID: PMCPMC3165215.
- 15. Calcedo R, Vandenberghe L H, Gao G, Lin J, Wilson J M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009; 199(3):381-90. doi: 10.1086/595830. PubMed PMID: 19133809.
- 16. Bainbridge J W, Smith A J, Barker S S, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008; 358(21):2231-9. doi: 10.1056/NEJMoa0802268. PubMed PMID: 18441371.
- 17. Maguire A M, High K A, Auricchio A, Wright J F, Pierce E A, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a
phase 1 dose-escalation trial. Lancet. 2009; 374(9701):1597-605. doi: 10.1016/S0140-6736(09)61836-5. PubMed PMID: 19854499; PubMed Central PMCID: PMCPMC4492302. - 18. Maguire A M, Simonelli F, Pierce E A, Pugh E N, Jr., Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008; 358(21):2240-8. doi: 10.1056/NEJMoa0802315. PubMed PMID: 18441370; PubMed Central PMCID: PMCPMC2829748.
- 19. Jacobson S G, Cideciyan A V, Ratnakaram R, Heon E, Schwartz S B, Roman A J, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012; 130(1):9-24. doi: 10.1001/archophthalmo1.2011.298. PubMed PMID: 21911650; PubMed Central PMCID: PMCPMC3600816.
- 20. Kaplitt M G, Feigin A, Tang C, Fitzsimons H L, Mattis P, Lawlor P A, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369(9579):2097-105. doi: 10.1016/S0140-6736(07)60982-9. PubMed PMID: 17586305.
- 21. Leone P, Shera D, McPhee S W, Francis J S, Kolodny E H, Bilaniuk L T, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med. 2012; 4(165):165ra3. doi: 10.1126/scitranslmed.3003454. PubMed PMID: 23253610; PubMed Central PMCID: PMCPMC3794457.
- 22. Manno C S, Pierce G F, Arruda V R, Glader B, Ragni M, Rasko J J, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006; 12(3):342-7. doi: 10.1038/nm1358. PubMed PMID: 16474400.
- 23. Nathwani A C, Tuddenham E G, Rangarajan S, Rosales C, McIntosh J, Linch D C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365(25):2357-65. doi: 10.1056/NEJMoa1108046. PubMed PMID: 22149959; PubMed Central PMCID: PMCPMC3265081.
- 24. Carpentier A C, Frisch F, Labbe S M, Gagnon R, de Wal J, Greentree S, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012; 97(5):1635-44. doi: 10.1210/jc.2011-3002. PubMed PMID: 22438229.
- 25. Manno C S, Chew A J, Hutchison S, Larson P J, Herzog R W, Arruda V R, et al. AAV-mediated factor I X gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003; 101(8):2963-72. doi: 10.1182/blood-2002-10-3296. PubMed PMID: 12515715.
- 26. Jaski B E, Jessup M L, Mancini D M, Cappola T P, Pauly D F, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-
human phase 1/2 clinical trial. J Card Fail. 2009; 15(3):171-81. doi: 10.1016/j.cardfail.2009.01.013. PubMed PMID: 19327618; PubMed Central PMCID: PMCPMC2752875. - 27. Ran F A, Cong L, Yan W X, Scott D A, Gootenberg J S, Kriz A J, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. doi: 10.1038/nature14299. PubMed PMID: 25830891; PubMed Central PMCID: PMCPMC4393360.
- 28. Balazs A B, Chen J, Hong C M, Rao D S, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011; 481(7379):81-4. doi: 10.1038/nature10660. PubMed PMID: 22139420; PubMed Central PMCID: PMCPMC3253190.
- 29. Gardner M R, Kattenhorn L M, Kondur H R, von Schaewen M, Dorfman T, Chiang J J, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015; 519(7541):87-91. doi: 10.1038/nature14264. PubMed PMID: 25707797; PubMed Central PMCID: PMCPMC4352131.
- 30. Adam V S, Crosariol M, Kumar S, Ge M Q, Czack S E, Roy S, et al. Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol. 2014; 21(11):1528-33. doi: 10.1128/CVI.00572-14. PubMed PMID: 25209558; PubMed Central PMCID: PMCPMC4248762.
- 31. Balazs A B, Bloom J D, Hong C M, Rao D S, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol. 2013; 31(7):647-52. doi: 10.1038/nbt.2618. PubMed PMID: 23728362; PubMed Central PMCID: PMCPMC4030719.
- 32. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015; 33(1):102-6. doi: 10.1038/nbt.3055. PubMed PMID: 25326897; PubMed Central PMCID: PMCPMC4492112.
- 33. Gene-therapy trials must proceed with caution. Nature. 2016; 534(7609):590. doi: 10.1038/534590a. PubMed PMID: 27357758.
- 34. Retracing events. Nat Biotechnol. 2007; 25(9):949. doi: 10.1038/nbt0907-949. PubMed PMID: 17846606.
- 35. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001; 164(11):1612. PubMed PMID: 11402803; PubMed Central PMCID: PMCPMC81135.
- 36. Martino A T, Suzuki M, Markusic D M, Zolotukhin I, Ryals R C, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011; 117(24):6459-68. doi: 10.1182/blood-2010-10-314518. PubMed PMID: 21474674; PubMed Central PMCID: PMCPMC3123017.
- 37. Zaiss A K, Liu Q, Bowen G P, Wong N C, Bartlett J S, Muruve D A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002; 76(9):4580-90. PubMed PMID: 11932423; PubMed Central PMCID: PMCPMC155101.
- 38. Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. Front Immunol. 2014; 5:82. doi: 10.3389/fimmu.2014.00082. PubMed PMID: 24624131; PubMed Central PMCID: PMCPMC3939780.
- 39. Manning W C, Paliard X, Zhou S, Pat Bland M, Lee A Y, Hong K, et al. Genetic immunization with adeno-associated virus vectors expressing herpes
simplex virus type 2 glycoproteins B and D. J Virol. 1997; 71(10):7960-2. PubMed PMID: 9311887; PubMed Central PMCID: PMCPMC192154. - 40. Liu D W, Tsao Y P, Kung J T, Ding Y A, Sytwu H K, Xiao X, et al. Recombinant adeno-associated virus expressing
human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol. 2000; 74(6):2888-94. PubMed PMID: 10684306; PubMed Central PMCID: PMCPMC111780. - 41. Xin K Q, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther. 2001; 12(9):1047-61. doi: 10.1089/104303401750214276. PubMed PMID: 11399227.
- 42. Breous E, Somanathan S, Bell P, Wilson J M Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology. 2011; 141(1):348-57, 57 e1-3. doi: 10.1053/j.gastro.2011.04.002. PubMed PMID: 21640112; PubMed Central PMCID: PMCPMC3269906.
- 43. Wang L, Wang H, Bell P, McCarter R J, He J, Calcedo R, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther. 2010; 18(1):118-25. doi: 10.1038/mt.2009.246. PubMed PMID: 19861950; PubMed Central PMCID: PMCPMC2839210.
- 44. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009; 119(8):2388-98. doi: 10.1172/JCI37607. PubMed PMID: 19587448; PubMed Central PMCID: PMCPMC2719948.
- 45. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008; 60(7):795-804. doi: 10.1016/j.addr.2007.12.004. PubMed PMID: 18262306.
- 46. Rogers G L, Martino A T, Aslanidi G V, Jayandharan G R, Srivastava A, Herzog R W. Innate Immune Responses to AAV Vectors. Front Microbiol. 2011; 2:194. doi: 10.3389/fmicb.2011.00194. PubMed PMID: 21954398; PubMed Central PMCID: PMCPMC3175613.
- 47. Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012; 55(1):287-97. doi: 10.1002/hep.24625. PubMed PMID: 21898480.
- 48. Hensley S E, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Mol Ther. 2007; 15(8):1417-22. doi: 10.1038/sj.mt.6300217. PubMed PMID: 17551505.
- 49. Lenert P S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010; 2010:986596. doi: 10.1155/2010/986596. PubMed PMID: 20490286; PubMed Central PMCID: PMCPMC2873634.
- 50. Trieu A, Roberts T L, Dunn J A, Sweet M J, Stacey K J. DNA motifs suppressing TLR9 responses. Crit Rev Immunol. 2006; 26(6):527-44. PubMed PMID: 17341193.
- 51. Krieg A M, Wu T, Weeratna R, Efler S M, Love-Homan L, Yang L, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA. 1998; 95(21):12631-6. PubMed PMID: 9770537; PubMed Central PMCID: PMCPMC22882.
- 52. Gursel I, Gursel M, Yamada H, Ishii K J, Takeshita F, Klinman D M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003; 171(3):1393-400. PubMed PMID: 12874230.
- 53. Stunz L L, Lenert P, Peckham D, Yi A K, Haxhinasto S, Chang M, et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002; 32(5):1212-22. doi: 10.1002/1521-4141(200205)32:5< 1212::AID-IMMU1212> 3.0.00; 2-D. PubMed PMID: 11981808.
- 54. Lenert P, Rasmussen W, Ashman R F, Ballas Z K. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and N K-cell lytic activity in mouse spleen cells. DNA Cell Biol. 2003; 22(10):621-31. doi: 10.1089/104454903770238094. PubMed PMID: 14611683.
- 55. Lenert P, Yasuda K, Busconi L, Nelson P, Fleenor C, Ratnabalasuriar R S, et al. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. Arthritis Res Ther. 2009; 11(3):R79. doi: 10.1186/ar2710. PubMed PMID: 19476613; PubMed Central PMCID: PMCPMC2714127.
- 56. Lenert P S. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther. 2006; 8(1):203. doi: 10.1186/ar1888. PubMed PMID: 16542467; PubMed Central PMCID: PMCPMC1526546.
- 57. Kaminski J J, Schattgen S A, Tzeng T C, Bode C, Klinman D M, Fitzgerald K A. Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. J Immunol. 2013; 191(7):3876-83. doi: 10.4049/jimmunol.1300530. PubMed PMID: 23986531; PubMed Central PMCID: PMCPMC3878640.
- 58. Shirota H, Gursel I, Gursel M, Klinman D M. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005; 174(8):4579-83. PubMed PMID: 15814679.
- 59. Peter M, Bode K, Lipford G B, Eberle F, Heeg K, Dalpke A H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology. 2008; 123(1):118-28. doi: 10.1111/j.1365-2567.2007.02718.x. PubMed PMID: 17961163; PubMed Central PMCID: PMCPMC2433270.
- 60. Ohto U, Shibata T, Tanji H, Ishida H, Krayukhina E, Uchiyama S, et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature. 2015; 520(7549):702-5. doi: 10.1038/nature14138. PubMed PMID: 25686612.
- 61. Li Y, Cao H, Wang N, Xiang Y, Lu Y, Zhao K, et al. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. Vaccine. 2011; 29(11):2193-8. doi: 10.1016/j.vaccine.2010.10.042. PubMed PMID: 21036131.
- 62. Xiong W, MacColl Garfinkel A E, Li Y, Benowitz L I, Cepko C L. NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest. 2015; 125(4):1433-45. doi: 10.1172/JCI79735. PubMed PMID: 25798616; PubMed Central PMCID: PMCPMC4396467.
- 63. Mingozzi F, High K A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013; 122(1):23-36. doi: 10.1182/blood-2013-01-306647. PubMed PMID: 23596044; PubMed Central PMCID: PMCPMC3701904.
- 64. Karlstetter M, Ebert S, Langmann T. Microglia in the healthy and degenerating retina: insights from novel mouse models. Immunobiology. 2010; 215(9-10):685-91. doi: 10.1016/j.imbio.2010.05.010. PubMed PMID: 20573418.
- 65. Chinnery H R, Naranjo Golborne C, Leong C M, Chen W, Forrester J V, McMenamin P G. Retinal Microglial Activation Following Topical Application of Intracellular Toll-Like Receptor Ligands. Invest Ophthalmol Vis Sci. 2015; 56(12):7377-86. doi: 10.1167/iovs.15-17587. PubMed PMID: 26574796.
- 66. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol. 2009; 175(5):2121-32. doi: 10.2353/ajpath.2009.090418. PubMed PMID: 19834064; PubMed Central PMCID: PMCPMC2774075.
- 67. Chinnery H R, McLenachan S, Binz N, Sun Y, Forrester J V, Degli-Esposti M A, et al. TLR9 ligand CpG-ODN applied to the injured mouse cornea elicits retinal inflammation. Am J Pathol. 2012; 180(1):209-20. doi: 10.1016/j.ajpath.2011.09.041. PubMed PMID: 22085974; PubMed Central PMCID: PMCPMC3338340.
- 68. Ye G J, Budzynski E, Sonnentag P, Nork T M, Miller P E, Sharma A K, et al. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. Hum Gene Ther Clin Dev. 2016. doi: 10.1089/hum.2015.164. PubMed PMID: 26956923.
- 69. Komaromy A M, Alexander J J, Rowlan J S, Garcia M M, Chiodo V A, Kaya A, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010; 19(13):2581-93. doi: 10.1093/hmg/ddq136. PubMed PMID: 20378608; PubMed Central PMCID: PMCPMC2883338.
- 70. Schoenborn J R, Wilson C B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96:41-101. doi: 10.1016/S0065-2776(07)96002-2. PubMed PMID: 17981204.
- 71. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene ibal in the major histocompatibility complex class III region encoding an E F hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun. 1996; 224(3):855-62. doi: 10.1006/bbrc.1996.1112. PubMed PMID: 8713135.
- 72. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998; 57(1):1-9. PubMed PMID: 9630473.
- 73. Gray J T, Zolotukhin S. Design and construction of functional AAV vectors. Methods Mol Biol. 2011; 807:25-46. doi: 10.1007/978-1-61779-370-7_2. PubMed PMID: 22034025.
- 74. Matsuda T, Cepko C L. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA. 2004; 101(1):16-22. doi: 10.1073/pnas.2235688100. PubMed PMID: 14603031; PubMed Central PMCID: PMCPMC314130.
- 75. Wang S, Sengel C, Emerson M M, Cepko C L. A gene regulatory network controls the binary fate decision of rod and bipolar cells in the vertebrate retina. Dev Cell. 2014; 30(5):513-27. doi: 10.1016/j.devcel.2014.07.018. PubMed PMID: 25155555; PubMed Central PMCID: PMCPMC4304698.
- 76. Martino A T, Herzog R W, Anegon I, Adjali O. Measuring immune responses to recombinant AAV gene transfer. Methods Mol Biol. 2011; 807:259-72. doi: 10.1007/978-1-61779-370-7_11. PubMed PMID: 22034034; PubMed Central PMCID: PMCPMC3593270.
Claims (25)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/167,764 US20190316151A1 (en) | 2016-06-08 | 2018-10-23 | Engineered viral vector reduces induction of inflammatory and immune responses |
US18/332,109 US20240043849A1 (en) | 2016-06-08 | 2023-06-09 | Engineered viral vector reduces induction of inflammatory and immune responses |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662347302P | 2016-06-08 | 2016-06-08 | |
PCT/US2017/036525 WO2017214378A1 (en) | 2016-06-08 | 2017-06-08 | Engineered viral vector reduces induction of inflammatory and immune responses |
US16/167,764 US20190316151A1 (en) | 2016-06-08 | 2018-10-23 | Engineered viral vector reduces induction of inflammatory and immune responses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/036525 Continuation WO2017214378A1 (en) | 2016-06-08 | 2017-06-08 | Engineered viral vector reduces induction of inflammatory and immune responses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/332,109 Continuation US20240043849A1 (en) | 2016-06-08 | 2023-06-09 | Engineered viral vector reduces induction of inflammatory and immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190316151A1 true US20190316151A1 (en) | 2019-10-17 |
Family
ID=60578967
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/308,420 Active 2038-12-27 US11339396B2 (en) | 2016-06-08 | 2017-06-08 | Engineered viral vector reduces induction of inflammatory and immune responses |
US16/167,764 Abandoned US20190316151A1 (en) | 2016-06-08 | 2018-10-23 | Engineered viral vector reduces induction of inflammatory and immune responses |
US18/332,109 Pending US20240043849A1 (en) | 2016-06-08 | 2023-06-09 | Engineered viral vector reduces induction of inflammatory and immune responses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/308,420 Active 2038-12-27 US11339396B2 (en) | 2016-06-08 | 2017-06-08 | Engineered viral vector reduces induction of inflammatory and immune responses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/332,109 Pending US20240043849A1 (en) | 2016-06-08 | 2023-06-09 | Engineered viral vector reduces induction of inflammatory and immune responses |
Country Status (7)
Country | Link |
---|---|
US (3) | US11339396B2 (en) |
EP (1) | EP3468605A4 (en) |
JP (2) | JP7034951B2 (en) |
KR (1) | KR20190017872A (en) |
CN (2) | CN109451729B (en) |
AU (2) | AU2017277647B2 (en) |
WO (1) | WO2017214378A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11339396B2 (en) | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
WO2022187679A1 (en) * | 2021-03-04 | 2022-09-09 | Kriya Therapeutics, Inc. | Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same |
US11981911B2 (en) | 2017-11-08 | 2024-05-14 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10736957B2 (en) | 2017-12-19 | 2020-08-11 | President And Fellows Of Harvard College | Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences |
SG11202107922QA (en) * | 2019-01-24 | 2021-08-30 | Generation Bio Co | Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response |
EP3927723A1 (en) | 2019-02-22 | 2021-12-29 | Life Technologies Corporation | Suspension system for adeno associated virus production |
WO2020232211A1 (en) * | 2019-05-15 | 2020-11-19 | President And Fellows Of Harvard College | Compositions and methods for inhibiting nucleic acid vector- induced inflammatory responses |
BR112022017735A2 (en) * | 2020-03-05 | 2022-11-29 | Flagship Pioneering Innovations Vi Llc | HOST DEFENSE SUPPRESSION METHODS AND COMPOSITIONS TO MODULATE A GENOME |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104314A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
DE69840850D1 (en) | 1997-06-06 | 2009-07-09 | Dynavax Tech Corp | INHIBITORS OF IMMUNSTIMULATORY DNA SEQUENCE ACTIVITY |
US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
ES2296615T3 (en) | 1999-04-08 | 2008-05-01 | Antisoma Research Limited | ANTIPROLIFERATIVE ACTIVITY OF OLIGONUCLEOTIDOS RICH IN G AND PROCEDURE OF USE OF THE SAME FOR YOUR JOINT TO NUCLEOLINE. |
ATE304361T1 (en) | 1999-09-25 | 2005-09-15 | Univ Iowa Res Found | IMMUNO-STIMULATING NUKEIN ACIDS |
MXPA00011713A (en) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars. |
WO2002057480A2 (en) | 2001-01-22 | 2002-07-25 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
WO2004012669A2 (en) | 2002-08-01 | 2004-02-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
NZ535952A (en) | 2002-04-04 | 2009-01-31 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
US20050013812A1 (en) | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
WO2005072097A2 (en) | 2003-12-16 | 2005-08-11 | University Of Massachusetts | Toll-like receptor 9 modulators |
EP1751612B1 (en) | 2004-05-06 | 2009-02-25 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for the treatment of uveitis |
EP1784501B1 (en) | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
WO2008104985A2 (en) | 2007-03-01 | 2008-09-04 | Rosetta Genomics Ltd. | Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers |
AU2005248149A1 (en) | 2004-05-26 | 2005-12-08 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
EP2305693B1 (en) | 2004-09-01 | 2015-07-15 | Dynavax Technologies Corporation | Methods and compositions for inhibition of innate immune responses and autoimmunity |
JP2008000001A (en) | 2004-09-30 | 2008-01-10 | Osaka Univ | Immune stimulating oligonucleotide and use in pharmaceutical |
WO2006066003A2 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
US20070077231A1 (en) | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
EP2343307B1 (en) | 2005-10-12 | 2015-08-05 | Idera Pharmaceuticals | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
WO2007127428A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
CA2655357A1 (en) | 2006-06-13 | 2007-12-21 | Bayhill Therapeutics, Inc. | Polynucleotide therapy |
US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
WO2008076981A2 (en) | 2006-12-15 | 2008-06-26 | Board Of Regents, The University Of Texas System | Inhibitors of ll-37- mediated immune reactivity to self nucleic acids |
WO2009006141A2 (en) | 2007-07-05 | 2009-01-08 | Bausch & Lomb Incorporated | Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
US7879812B2 (en) | 2007-08-06 | 2011-02-01 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides and methods of use therefor |
WO2009023819A2 (en) | 2007-08-15 | 2009-02-19 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
CA2703931C (en) | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
WO2009089401A2 (en) | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
WO2009089399A2 (en) | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
US8222225B2 (en) | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
JP5415724B2 (en) * | 2008-08-05 | 2014-02-12 | 長春華普生物技術有限公司 | A kind of oligonucleotide and its application |
US8030289B2 (en) | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
WO2010034779A2 (en) * | 2008-09-24 | 2010-04-01 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Composition and method for treatment of preterm labor |
GB0906130D0 (en) | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
MX2011003625A (en) | 2008-10-06 | 2011-05-31 | Idera Pharmaceuticals Inc | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto. |
US8053422B2 (en) | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
WO2010108035A1 (en) * | 2009-03-18 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating toxic and proinflammatory effects |
WO2010127166A2 (en) | 2009-04-30 | 2010-11-04 | The Regents Of The University Of California | Combination anti-hiv vectors, targeting vectors, and methods of use |
ES2624767T3 (en) | 2009-06-01 | 2017-07-17 | Idera Pharmaceuticals, Inc | Enhancement of autoimmune and inflammatory disease treatments using immunoregulatory oligonucleotides (IRO) antagonists of TLR7 and TLR9 |
US20110070241A1 (en) | 2009-06-30 | 2011-03-24 | Duke University | Methods for modulating immune responses to aav gene therapy vectors |
EP2451974A2 (en) | 2009-07-08 | 2012-05-16 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
CN101712957B (en) * | 2009-11-25 | 2011-11-23 | 中国人民解放军第三军医大学第一附属医院 | Toll-like receptor 9 (TLR9) blocking agent and application thereof |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
CA2833912C (en) | 2010-04-23 | 2021-09-21 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
JP5921535B2 (en) | 2010-06-16 | 2016-05-24 | ディナバックス テクノロジーズ コーポレイション | Methods of treatment using TLR7 and / or TLR9 inhibitors |
AU2011268211B2 (en) | 2010-06-16 | 2015-07-16 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
GB201014026D0 (en) | 2010-08-20 | 2010-10-06 | Ucl Business Plc | Treatment |
WO2012051491A1 (en) * | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
ES2697606T3 (en) | 2010-11-19 | 2019-01-25 | Idera Pharmaceuticals Inc | Immunoregulatory oligonucleotide (IRO) compounds to modulate the immune response based on a Toll-like receptor |
WO2013116590A1 (en) | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
AR091569A1 (en) | 2012-06-28 | 2015-02-11 | Intervet Int Bv | TOLL TYPE RECEIVERS |
CN104797593B (en) | 2012-09-28 | 2020-05-08 | 北卡罗来纳-查佩尔山大学 | AAV vectors targeting oligodendrocytes |
CN102925485B (en) | 2012-11-09 | 2014-07-09 | 中国农业科学院兰州兽医研究所 | Preparation method of dually-expressed AAV (Adeno Associated Virus) recombinant virus |
US9688992B2 (en) | 2012-11-29 | 2017-06-27 | Sbi Biotech Co., Ltd. | Inhibitory oligonucleotide and use thereof |
US9453209B2 (en) * | 2012-12-27 | 2016-09-27 | Sierra Sciences, Llc | Enhancing health in mammals using telomerase reverse transcriptase gene therapy |
WO2014110081A1 (en) | 2013-01-08 | 2014-07-17 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
JP2017500313A (en) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー, インコーポレーテッドBullet Biotechnology, Inc. | Specific virus-like particle-CpG oligonucleotide vaccine and uses thereof |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
EP2982756A1 (en) | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
US20170333565A1 (en) | 2014-10-31 | 2017-11-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted cytotoxic agents |
WO2016130832A1 (en) | 2015-02-13 | 2016-08-18 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
WO2016149618A1 (en) | 2015-03-19 | 2016-09-22 | The Johns Hopkins University | Method for regulation of telomere-length |
US10775367B2 (en) | 2015-04-15 | 2020-09-15 | Ji Hoon Lee | Aptasensor and method of detecting target material |
WO2016183370A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage |
DK3329004T3 (en) | 2015-07-29 | 2020-04-20 | Ifom Fondazione St Firc Di Oncologia Molecolare | THERAPEUTIC OLIGONUCLEOTIDES |
US10653687B2 (en) | 2015-11-18 | 2020-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compostions for treating rhabdomyolysis |
CA3009154A1 (en) | 2015-12-25 | 2017-06-29 | Sbi Biotech Co., Ltd. | Tlr inhibitory oligonucleotides and their use |
CN105597079A (en) * | 2016-01-11 | 2016-05-25 | 中国人民解放军第三军医大学第一附属医院 | Medicine for treating psoriasis |
US10124062B2 (en) | 2016-02-26 | 2018-11-13 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods of treating, inhibiting and/or preventing an auditory impairment |
EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
US10947545B2 (en) | 2016-11-23 | 2021-03-16 | Berlin Cures GmbH | Aptamers for use in inhibition and/or suppression of TLR9 activation |
US11981911B2 (en) | 2017-11-08 | 2024-05-14 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
-
2017
- 2017-06-08 EP EP17811006.0A patent/EP3468605A4/en active Pending
- 2017-06-08 US US16/308,420 patent/US11339396B2/en active Active
- 2017-06-08 CN CN201780045910.3A patent/CN109451729B/en active Active
- 2017-06-08 WO PCT/US2017/036525 patent/WO2017214378A1/en unknown
- 2017-06-08 KR KR1020197000132A patent/KR20190017872A/en not_active Application Discontinuation
- 2017-06-08 CN CN202210208639.3A patent/CN114807152A/en active Pending
- 2017-06-08 JP JP2018563666A patent/JP7034951B2/en active Active
- 2017-06-08 AU AU2017277647A patent/AU2017277647B2/en active Active
-
2018
- 2018-10-23 US US16/167,764 patent/US20190316151A1/en not_active Abandoned
-
2022
- 2022-03-02 JP JP2022031422A patent/JP7394898B2/en active Active
-
2023
- 2023-06-09 US US18/332,109 patent/US20240043849A1/en active Pending
- 2023-10-17 AU AU2023251424A patent/AU2023251424A1/en active Pending
Non-Patent Citations (1)
Title |
---|
Cui et al, Transcriptional Regulation of Gene Expression by microRNAs as Endogenous Decoys of Transcription Factors, Cell Physiol Biochem 2014;33:1698-1714 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11339396B2 (en) | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
US11981911B2 (en) | 2017-11-08 | 2024-05-14 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
WO2022187679A1 (en) * | 2021-03-04 | 2022-09-09 | Kriya Therapeutics, Inc. | Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
CN109451729A (en) | 2019-03-08 |
WO2017214378A1 (en) | 2017-12-14 |
US20240043849A1 (en) | 2024-02-08 |
US11339396B2 (en) | 2022-05-24 |
KR20190017872A (en) | 2019-02-20 |
JP2019517266A (en) | 2019-06-24 |
AU2017277647A1 (en) | 2018-12-13 |
JP2022066336A (en) | 2022-04-28 |
JP7394898B2 (en) | 2023-12-08 |
AU2017277647B2 (en) | 2023-07-27 |
JP7034951B2 (en) | 2022-03-14 |
AU2023251424A1 (en) | 2023-11-09 |
EP3468605A4 (en) | 2020-01-08 |
US20190177731A1 (en) | 2019-06-13 |
CN114807152A (en) | 2022-07-29 |
EP3468605A1 (en) | 2019-04-17 |
CN109451729B (en) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240043849A1 (en) | Engineered viral vector reduces induction of inflammatory and immune responses | |
JP7262134B2 (en) | Oncolytic HSV vectors | |
Dyka et al. | Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A | |
Ramlogan‐Steel et al. | Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations | |
KR102526711B1 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
CN105408352B (en) | Efficient delivery of large genes by dual AAV vectors | |
JP2022031769A (en) | Gene editing of deep intronic mutations | |
KR20160033217A (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
KR20160026841A (en) | Vectors comprising stuffer/filler polynucleotide sequences and methods of use | |
US20110117058A1 (en) | Method of treating genetic disorders | |
TW201741458A (en) | Gene therapy for treating hemophilia A | |
US20110070241A1 (en) | Methods for modulating immune responses to aav gene therapy vectors | |
TW201629225A (en) | Factor IX gene therapy | |
US11981911B2 (en) | Compositions and methods for inhibiting viral vector-induced inflammatory responses | |
CN114072514A (en) | Compositions and methods for treating ATPase mediated diseases | |
JP7406253B2 (en) | Immune evasive vectors and use for gene therapy | |
US20190010517A1 (en) | Methods and compositions for facilitating homologous recombination | |
WO2023169115A1 (en) | Aav vector having high affinity with nervous system, and application thereof | |
KR102545070B1 (en) | Gene Therapy for Eye Disorders | |
CN112840020B (en) | Oncolytic virus and uses thereof | |
Chamberlain et al. | A calsequestrin cis-regulatory motif coupled to a cardiac troponin T promoter improves cardiac adeno-associated virus serotype 9 transduction specificity | |
CN114144518A (en) | Dual leucine zipper kinase inhibitors for gene therapy | |
Cho et al. | Safety and efficacy evaluations of an adeno-associated virus variant for preparing IL10-secreting human neural stem cell-based therapeutics | |
US20220133909A1 (en) | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design | |
JP2023548746A (en) | Viral vector constructs for delivering nucleic acids encoding cytokines and their use for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAN, YING KAI;CHURCH, GEORGE M.;SIGNING DATES FROM 20170920 TO 20170925;REEL/FRAME:047510/0932 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |